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CHAPTER 1 
 
Introduction to Muscular Dystrophies Related to Mutations in the 
Dystrophin-Glycoprotein Complex 
 
Skeletal muscle is a dynamic tissue that routinely undergoes a significant 
degree of mechanical strain and cellular deformation with each contraction.  In 
order to preserve normal skeletal muscle function throughout the lifetime of an 
individual, this complex tissue must be able to routinely undergo cell shortening 
and generate forces required for movement while at the same time limiting 
mechanical cellular injury and adapting to changing workloads.  In muscular 
dystrophy, an imbalance between muscle damage or degeneration and muscle 
repair through stem-cell mediated regeneration is thought to contribute to the 
disease pathology and consequently results in a progressive decline in muscle 
function (1).  Mutations in a number of distinct genes can cause muscular 
dystrophy with varying degrees of severity, but precisely how each can 
negatively affect normal muscle function is unclear (2).  Several muscular 
dystrophies result from mutations that affect the normal assembly of the 
dystrophin-glycoprotein complex at the sarcolemma in muscle and therefore, 
highlight the importance of this complex in normal muscle function.  Within the 
DGC, the protein dystroglycan serves as an essential glycosylation-mediated 
extracellular matrix receptor and this receptor function is impaired in a number of 
congenital muscular dystrophies caused by mutations in glycosyltransferases.  In 
addition to muscle disease, patients with glycosylation-deficient muscular 
dystrophy also demonstrate impairments in both the central and peripheral 
nervous system as a consequence of altered dystroglycan function.   While this 
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suggests that dystroglycan has a critical glycosylation-mediated function in both 
striated muscle and the nervous system, the molecular mechanism that accounts 
for the wide clinical spectrum associated with these diseases is poorly 
understood and the basis for the work described in this dissertation.  The goal of 
this research is to understand how mutations in the putative glycosyltransferase 
LARGE impair dystroglycan function and cause a multi-system muscle disease.  
Because the primary function of dystroglycan within the DGC is thought to be 
predominantly structural in skeletal muscle, initial experiments were focused on 
understanding how impaired or enhanced LARGE-mediated glycosylation of 
dystroglycan affected skeletal muscle function.  In later experiments, a novel 
transgenic mouse was used to dissect the functions of dystroglycan in neural 
tissues that contribute to disease progression in glycosylation-deficient muscular 
dystrophy.  In order to understand how dystroglycan may function in multiple 
tissues, this introduction will summarize both the literature supporting a 
mechanical function for the DGC, and the recent evidence highlighting additional 
functions of the DGC in muscle and non-muscle tissues that when impaired, can 
result in the spectrum of clinical symptoms associated with glycosylation-deficient 
muscular dystrophy. 
The DGC, Sarcolemma Integrity, and Contraction-Induced Muscle Injury 
A longstanding hypothesis to explain the muscle damage and degeneration 
observed in dystrophic muscle is that mutations affect the function of critical 
structural proteins in muscle and compromise the mechanical stability of the 
muscle fiber and/or the integrity of sarcolemma.  This exacerbates the damage 
that occurs during normal muscle contractions and initiates a lethal cascade of 
events that can cause death of the myofiber (3-5).  In support of this, early 
studies demonstrated an increase in the number of necrotic fibers in muscles 
from muscular dystrophy patients that likely resulted from irreparable membrane 
damage as a consequence of normal muscle activity (6).  However, rather than 
dystrophic muscle suffering from an increased susceptibility to external damage, 
alternative hypotheses exist that could account for increased cell death.  For 
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example, causative mutations may affect either the resting homeostasis of 
muscle cells or alter the ability of the muscle to adapt and repair following a 
normal “dose” of muscle injury.  Although the importance of the dystrophin-
glycoprotein complex in maintaining sarcolemma integrity is well supported, 
alternative functions for this complex have been proposed through the years and 
are now gaining significant experimental support (7, 8).   
The dystrophin-glycoprotein complex (DGC) is composed of several 
transmembrane and peripheral components, and is highly expressed in the 
sarcolemma of skeletal muscle (9-11).  Mutations in genes that encode DGC 
components lead to the loss of either expression and/or function of the DGC in 
muscle.  Dystroglycan is a protein central to this complex that spans the 
sarcolemma linking the cellular cytoskeleton to the surrounding basal lamina 
through dystrophin (within the cell) and α-dystroglycan (on the cell surface) (12).  
Dystrophin in turn binds to the submembrane actin and intermediate filament 
cytoskeleton within fibers, thereby completing a link between the cytoskeleton 
and the extracellular matrix (13, 14).  Costameres are concentrations of 
extracellular matrix receptor complexes that reside at the membrane in register 
with the Z-lines of sarcomeres within muscle fibers (15).  The location of the DGC 
at costameres and the identification of its function as a link between the matrix 
and the cytoskeleton led to the hypothesis that the DGC might be critical in 
mechanically stabilizing muscle or the sarcolemma during muscle contraction 
(12, 16).  In addition to dystroglycan and dystrophin, the core of this complex in 
skeletal muscle includes four sarcoglycans (α, β, γ, and δ) and sarcospan, which 
are thought to contribute to stabilization of the complex within the sarcolemma.  
Mutations in either dystrophin or the sarcoglycans are associated with reduced 
expression or incomplete formation of the DGC (17-19) and are hypothesized to 
result in muscular dystrophy through a common mechanism which includes a 
reduction in dystroglycan function.  Therefore, reduction in the connections 
between the cytoskeleton and the extracellular matrix are a critical feature of 
muscular dystrophies associated with the DGC.   
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In addition to primary mutations in DGC components, several causative 
mutations have also been identified in a group of glycosyltransferases, which 
have been shown to function in a common pathway to glycosylate α-
dystroglycan.  This O-linked glycosylation of α-dystroglycan is essential for 
enabling α-dystroglycan to function as an extracellular matrix receptor (20).   In 
these glycosylation-deficient muscular dystrophies, dystroglycan and the DGC 
are expressed and intact at the sarcolemma, but the loss of dystroglycan’s ability 
to bind laminin is sufficient to cause muscular dystrophy (21, 22).  These findings 
highlight specifically the interaction of the DGC with extracellular matrix as a 
critical function of the DGC in preventing muscular dystrophy.    
In dystroglycan glycosylation-deficient mice (LARGEmyd), electron 
microscopic analysis showed that the interaction of dystroglycan with laminin in 
the extracellular matrix appeared to tightly anchor the basal lamina to the 
sarcolemma (22).  This tight and regular interaction of dystroglycan with the 
basal lamina is proposed to protect the sarcolemma from expansion of small 
ruptures during mechanical activity.  Mutations in dystroglycan itself appear to be 
quite rare in humans, perhaps related to an essential role of dystroglycan in early 
development (23).  Only recently has a mutation in the dystroglycan gene been 
identified in muscular dystrophy patients and like previous glycosyltransferase 
mutations, the mutation appears to impair dystroglycan glycosylation causing 
loss of function without impacting dystroglycan expression (24).   
The heterotrimeric protein laminin-211, which is bound by glycosylated α-
dystroglycan, is a major component of the basal lamina surrounding adult muscle 
fibers. Mutations in the LAMA2 gene result in loss of laminin α2 expression and 
the most common form of congenital muscular dystrophy (25-27).  The 
identification of laminin α2 mutations only further reinforces the notion that any 
disruption of the connection between the muscle fiber cytoskeleton to the 
extracellular matrix through the DGC, whether it be reduced expression of the 
DGC, reduced ability of dystroglycan to interact with laminin, or loss of laminin 
itself from the basal lamina, is sufficient to cause muscular dystrophy.   
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Despite the first genetic identification of dystrophin as a causal gene in 
Duchenne muscular dystrophy more than two decades ago (28) and the 
identification of the DGC in years following (17),  whether the DGC contributes 
purely a mechanical role in stabilizing the sarcolemma during normal 
contractions or imparts other significant functions in muscle still remains an area 
of active investigation.  The identification of additional components of the DGC, 
such as sarcospan, dystrobrevins and syntrophins, that do not appear to have a 
direct or essential role in the mechanical function of the DGC but instead appear 
to be docking sites for other intracellular signaling proteins (29), has fueled 
considerable interest in what other intracellular pathways may be affected in 
DGC-associated muscular dystrophies.    
Even normal skeletal muscle is susceptible to mechanical damage, 
particularly during lengthening contractions, and the resulting defects at the level 
of the sarcolemma (30), the t-tubules (31), or the contractile machinery (32) 
contribute to a transient decrease in the isometric force.  Following repetitive 
lengthening contractions, there can also be considerable, prolonged injury and 
muscle dysfunction that results from muscle degeneration, swelling, and 
infiltration of inflammatory cells (33).  In most cases, muscle dysfunction caused 
by prolonged injury can be fully repaired over time by active muscle fiber 
regeneration from resident stem cells, known as satellite cells.  This suggests 
that occasional sarcolemmal injuries, muscle damage and their repair is a critical 
component of the homeostasis of normal muscle.   
Many of the early experiments that sought to identify the mechanism by 
which mutations affecting the DGC cause muscular dystrophy have utilized the 
mdx mouse model (34).  These mice harbor a null mutation in the dystrophin 
gene and although they do exhibit the clinical features observed in human 
patients, the severity is milder (35).  A role for the function of dystrophin in 
maintaining the integrity of the sarcolemma during muscle contraction was 
supported by studies showing that mdx muscle was highly susceptible to 
lengthening contraction-induced injury performed in vitro, as compared to healthy 
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control muscle.  Muscle from mdx animals demonstrated an increased tendency 
to take up Procion orange dye from the bathing medium, which suggested an 
increase in sarcolemma permeability following contraction (4, 36).   When 
injected into mdx animals, the membrane-impermeant Evans blue dye was also 
selectively taken up by muscle fibers that appeared necrotic and 
hypercontracted, suggesting that increased membrane permeability eventually 
resulted in cell death (37).  This further supported the hypothesis that muscle 
contractions produce membrane tears, leading to increased permeability of the 
sarcolemma to calcium and small molecules and resulting in a greater degree of 
cell death in dystrophic muscle.  Muscle from mdx mice also demonstrated a 
measurable deficit in force generation following an in vivo lengthening contraction 
protocol (38, 39).  These data support a function for dystrophin and the 
dystrophin-glycoprotein complex in protecting the sarcolemma during muscle 
contraction and suggest that, in its absence, the sarcolemma is more susceptible 
to damage by contractile forces, resulting in increased permeability of ions and 
small molecules, and eventual cell necrosis and muscle degeneration.   
Further support for a critical role of membrane integrity in muscular 
dystrophies was gained from a different class of muscular dystrophies associated 
with mutations in the dysferlin gene.  Mutations in dysferlin are associated with 
Miyoshi myopathy and limb-girdle muscular dystrophy 2B in humans (40, 41).  
Dysferlin is not associated with the DGC but appears to have homology to the 
vesicle protein, synaptotagmin, and therefore has been predicted to be important 
for mediating vesicle-mediated membrane repair.  While the complete functions 
of dysferlin are still under investigation, dysferlin has been shown to be required 
for rapid resealing of the sarcolemma in a calcium-dependent manner following 
focal membrane damage (42).  Although muscle from dysferlin-null animals is not 
particularly susceptible to contraction-induced damage (43), a recent study 
demonstrated that recovery of muscle following damage required an immediate 
and transient membrane resealing event and that dysferlin-deficient muscle 
consequently took longer to recover (43, 44).  The identification of dysferlin as a 
potential mediator of membrane repair in muscle underlies the importance of 
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sarcolemmal integrity and its maintenance by repair pathways as important 
mechanisms in which defects may result in muscle degeneration. 
Does contraction-induced injury play a causal role in DGC-associated 
muscular degeneration and dystrophy? 
While the generally accepted dogma is that mutations affecting the DGC 
render muscle more susceptible to contraction-induced damage during 
mechanical stress (45), recent evidence from our laboratory suggests that not all 
muscles of dystrophic animals are equally affected (Chapter 2).  We reported 
that, in the LARGEmyd animal model of glycosyltransferase-deficient muscular 
dystrophy, typical fast-twitch muscles such as the EDL were weaker than in 
control muscle.  Additionally, although LARGEmyd EDL demonstrated the 
increased susceptibility to contraction-induced injury typical of mdx mice, a 
remarkably different phenotype was measured in soleus muscles, which are 
composed of mixtures of fast and slow fibers.  The fact that force deficits 
measured in wild-type soleus muscle were actually higher than those measured 
in EDL muscle after two lengthening contractions, suggests that the observed 
force defect in the EDL muscle of LARGEmyd mice was not due to inherent 
differences in susceptibility to injury between the two muscle groups.  However, 
the soleus of LARGEmyd animals was weaker than WT muscle and was 
dystrophic, as evidenced by an increase in degenerating fibers, accumulation of 
inflammatory cells, and the presence of centrally nucleated fibers.  An 
explanation that accounts for the dystrophic features and fiber degeneration in 
the soleus muscle in the absence of any detectable increased susceptibility to 
contraction-induced injury has not been addressed.  
A similar lack of increased susceptibility of muscle to contraction-induced 
muscle damage was previously demonstrated in the soleus of mdx mice, and the 
authors speculated that dystrophin was not essential for maintaining structural 
stability in the soleus muscle (38).  Utrophin, a homologue of dystrophin, has 
been shown to be upregulated in the absence of dystrophin (46) and is also more 
highly expressed in slow-twitch fibers (47) which may therefore confer a degree 
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of stability in the soleus muscle of mdx mice that might explain this lack of 
susceptibility to contraction-induced injury.  However, upregulation of utrophin 
cannot explain the results in LARGEmyd mice because, other than the loss of 
dystroglycan glycosylation, the DGC is assembled normally in LARGEmyd muscle 
(21, 22).  We found that another important laminin receptor in muscle, α7β1 
integrin, is expressed at much higher levels in the sarcolemma of soleus muscle 
as compared to other fast muscles (48).  Several reports have demonstrated that 
when the DGC is impaired, α7 or β1 integrin is upregulated,  which suggests that 
the two receptors may have at least some overlapping functions in muscle (49).  
Susceptibility to contraction-induced injury was directly compared  between α7 
integrin-null and LARGEmyd mice using EDL muscle and only LARGEmyd muscle 
was shown to be more susceptible to injury (22).  This might suggest that 
interactions with laminin and dystroglycan are more important for mechanical 
stability than are the interactions between α7β1 integrin and laminin.  However, 
α7β1 integrin expression in fast muscle is very low, and the comparison was only 
performed in fast-twitch muscle, and not in the soleus muscle, which remains to 
be studied.  Transgenic overexpression of α7 integrin in dystrophin/utrophin 
double knock-out mice can significantly improve muscle disease (50), but 
whether this beneficial effect is due to prevention of mechanical damage or 
effects on cell signaling has not been fully addressed.   
  Muscle physiological studies have also been performed in an animal 
model of congenital muscular dystrophy, the dy/dy mouse that harbors a null 
mutation in the LAMA2 gene (25).  In contrast to the results demonstrated in mdx 
mice, laminin-deficient muscle does not exhibit a defect in sarcolemmal stability 
(51).  Both the EDL and soleus muscles were isolated from laminin-deficient mice 
and subjected to a moderate lengthening contraction protocol in vitro and neither 
demonstrated an increased susceptibility to injury over that observed in control 
muscle.  As a means to amplify potentially subtle defects in these mice, the 
anesthetic halothane was used to increase fluidity of the lipid bilayer.  Although 
this caused an increase in force deficit following a lengthening contraction 
protocol, this deficit was still not any greater in laminin-deficient muscle (51).  
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Because contraction protocols can vary, sarcolemmal permeability was directly 
compared between three different mouse models of DGC-related muscular 
dystrophy,  mdx (34) and two deficient in laminin, dy/dy (25) and dy2j/dy2j (26).  
Animals were injected intravenously with Evans blue dye and muscles were 
analyzed several hours post injection.  Muscles from mdx demonstrated an 
increase in dye uptake while dye uptake in laminin-deficient muscle was not 
different than control animals (52).  Additionally, positively stained fibers in mdx 
mice often appeared in groups of neighboring fibers, in contrast to the few 
individual fibers stained in laminin-deficient muscle, which appeared necrotic.  
However, laminin-deficient muscle still had dystrophic pathological features, 
which further supports the notion that, although disruption of the sarcolemma 
may contribute to the pathology of muscle disease, it is not essential.  
Together, these studies demonstrate that membrane damage is not 
required for muscle degeneration and muscular dystrophy.  Although mutations 
that compromise DGC function can leave muscle vulnerable to membrane 
damage, this is not true for all muscle groups, since the soleus muscle, despite 
demonstrating a susceptibility to injury, does not show an increase in 
susceptibility in the absence of a functional DGC.  Additionally, the number of 
fibers that may be damaged, as evidenced by dye uptake in mdx fast muscles, is 
not sufficient to explain the dramatic loss in force generation following injury (38).  
Therefore, the DGC likely possesses other cellular functions in skeletal muscle 
that, when impaired, contribute to muscle degeneration and the dystrophic 
pathology.  Potential alternative pathways and their experimental support are 
reviewed below.   
Role of the DGC in Altered Calcium Homeostasis 
Intracellular calcium is a critical mediator of many regulatory processes in 
skeletal muscle (53).  In dystrophic muscle, the concentration of intracellular 
calcium is elevated, and several potential sources for calcium entry have now 
been identified (Fig. 1.1).  Early studies of mdx muscle demonstrated that 
individual fibers demonstrating an elevation in intracellular calcium were also 
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necrotic, suggesting that calcium entered through membrane tears as a direct 
result of dystrophin loss (54, 55).  Increased intracellular calcium in mdx muscle 
was later explained by an increase in sarcolemmal permeability attributed to 
calcium leak and stretched-activated channels (56, 57).  Stretch-activated 
channels can be blocked in mdx mice via oral delivery of streptomycin resulting 
in a reduction in intracellular calcium and an improvement in force production 
(58).  In the same study, a decrease in intracellular calcium was not observed in 
streptomycin-treated control animals, suggesting that the activity of these 
channels was enhanced in the absence of dystrophin.     
Transient receptor potential (TRP) channels are a diverse family of ion 
channels composed of multiple subunits that have also been identified as 
potential mediators of altered calcium homeostasis in dystrophic muscle (59).  
Several TRP channels in the canonical subfamily (TRPC) are expressed in 
mouse skeletal muscle and TRPC1, TRPC4 and TRPC6 were initially identified 
as being potentially impaired in mdx muscle (60).  In a later study, expression of 
TRPC1 was shown to be increased in mdx muscle and the authors speculated 
that its activity may be increased due to additional upregulation of caveolin-3 and 
src, which contribute to the translocation of  this channel to the sarcolemma (61).  
Similarly, a stretch-activated TRP channel in the vanilloid receptor subfamily, 
TRPV2, has also been shown to be more highly expressed at the sarcolemma in 
mdx muscle.  Inhibition of TRPV2 using a dominant negative genetic approach 
resulted in a restoration of normal intracellular calcium levels and an amelioration 
of dystrophic pathology in mdx mice (62).  
Although the increased resting calcium concentration observed in the 
cytoplasm of dystrophic muscle may be the result of increased expression or 
activity of calcium channels at the sarcolemma, a recent study has demonstrated 
that an additional source of calcium entry may be due to defects at the level of 
the sarcoplasmic reticulum (63).  RyR1 channels isolated from mdx muscle were 
shown to be hypernitrosylated as a potential consequence of altered nitric oxide 
signaling downstream of dystrophin loss.  This resulted in an increased leak of 
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calcium ions from the sarcoplasmic reticulum, and pharmacological inhibition of 
RyR1 was shown to reduce muscle damage in mdx muscle.    
While several of these studies noted an improvement in muscle health 
following inhibition of calcium entry in animal models of muscular dystrophy, an 
important study recently demonstrated that elevated calcium was sufficient to 
cause muscle damage in the absence of a genetic basis for muscular dystrophy 
(64).  The overexpression of TRPC3 in skeletal muscle resulted in a muscle 
wasting phenotype with defects similar to those observed in laminin-deficient 
muscle.  Using gene expression profiling, this phenotype was also shown to be 
associated with altered expression of many genes, in a pattern that was strikingly 
similar to gene expression changes in δ-sarcoglycan deficient muscle.  However, 
the muscle did not demonstrate any changes in expression of the DGC at the 
sarcolemma, suggesting that much of the muscle damage observed in DGC-
related muscular dystrophies may be attributed to downstream defects in calcium 
homeostasis. 
 Elevated intracellular calcium can result in cellular damage in a number of 
ways that may underlie many of the defects observed in dystrophic muscle.  
When sustained, abnormal elevations in intracellular calcium can cause 
mitochondria to undergo permeability transition which can eventually lead to 
mitochondrially mediated apoptosis, involving swelling of the mitochondria, 
release of cytochrome c and the activation of caspases (65).  Cyclophilin D is a 
mitochondrial enzyme that is important for regulating the mitochondrial 
permeability transition and genetic strategies have demonstrated that its absence 
renders mitochondria insensitive to calcium-induced cell death (66, 67).  Both δ-
sarcoglycan-null and laminin-null mice have abnormally swollen mitochondria 
and the muscular dystrophy seen in both models can be partially alleviated by 
altering the pores mediating the mitochondrial permeability transition (68).   
Another important downstream consequence of mitochondrial dysfunction 
is an increased production of reactive oxygen species (ROS), which can further 
exacerbate cellular damage (69).  Several studies have identified ROS as a 
12 
 
potential mediator of muscle damage in the muscular dystrophies (70-72).  
Antioxidant treatment of mdx mice has demonstrated mixed results but in some 
cases has lessened the symptoms of muscular dystrophy (72, 73).  In a model of 
muscular dystrophy not associated with DGC defects but instead caused by 
defective collagen IV, a component of the extracellular matrix, mitochondrial 
dysfunction was shown to be a major source of ROS.  Additionally, when ROS 
production was suppressed, oxidation of myofibrillar proteins was reduced and 
improved contractile performance (74). Therefore, cellular mechanisms 
downstream of mitochondrial defects may be an important step in the process by 
which DGC mutations eventually result in myofiber damage and cause muscle 
disease. 
 Normal excitation-contraction coupling has been suggested to be affected 
by an increase in cellular calcium concentration and may also be an important 
contributor to muscle weakness in these diseases (75, 76).  Elevated calcium 
can also directly impair muscle function by increasing the activity of calcium-
dependent proteases like calpains which can cleave myofibrillar proteins (77-79).  
While the genetic and pharmacological inhibition of calpains may alleviate 
several pathological features in mdx muscle (80-82), such experiments have 
yielded inconsistent results and may be in part due to compensatory increases in 
calpain activity and/or a lack of efficacy of the proposed inhibitors (83).   
 Several of these studies have demonstrated that intracellular calcium is 
elevated in dystrophic muscle and that this can lead to a number of deleterious 
effects to the cell and contribute to a decline in contractile function.  More 
importantly, these studies have provided several alternatives by which calcium 
permeability and/or intracellular calcium may be increasing that are independent 
from direct entry of calcium through sarcolemma tears.  However, it is still 
unclear just how distinct genetic mutations that affect the function of the DGC 
can alter activity of the various calcium channels that have been proposed.  
While inhibition of calcium entry has been shown to be beneficial in the animal 
models addressed, it is important to note that muscle disease was still present in 
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these animals, albeit it to a lesser degree.  This suggests that altered calcium 
homeostasis, whether it is through membrane tears or from altered activity of 
calcium channels, may not be the only mechanism downstream of genetic 
mutations that results in muscle damage. 
Laminin-Dependent Intracellular Signaling Through the DGC 
Laminins exist as heterotrimeric proteins composed of specific combinations of α, 
β, and γ subunits and are differentially expressed in multiple cell types.  Laminin-
211 (α2/β1/γ1) is expressed in the extracellular matrix of adult skeletal muscle 
and is bound with high affinity by α-DG and α7β1 integrin.  Mutations that affect 
α2 laminin, as is the case in the dy/dy mouse and in congenital muscular 
dystrophy 1A, result in muscular dystrophy as a result of lost interactions with 
either or both laminin receptors (25-27).  Although laminin is the major ligand of 
dystroglycan by which a connection is forged between the DGC and the 
extracellular matrix in skeletal muscle, laminin-211 deficient muscle is not 
susceptible to contraction-induced damage and does not typically show 
increased uptake of cell impermeant dye (reviewed above).  Despite the lack of 
evidence for increased muscle damage, many fibers of laminin-deficient muscle 
are apoptotic (84), which is thought to significantly contribute to muscle disease.  
Both pharmacological and genetic inhibition of apoptosis (e.g. Bcl-2 
overexpression, Bax inactivation) has been shown to ameliorate dystrophy in 
laminin α2 deficient animal models (85-88).  Because there appears to be a lack 
of sarcolemmal damage, the mechanism by which apoptosis occurs in this 
disease may be independent of elevations in intracellular calcium.  Alternatively, 
increases in apoptosis may be due to disruptions in downstream cell survival 
signaling as a result of lost interactions between laminin and its two major 
receptors in skeletal muscle.  
Potential increases in survival signaling through laminin receptors in 
muscle could be the basis for results of a recent study that demonstrated an 
improvement of dystrophy in mdx mice upon injection of soluble laminin-111, a 
laminin isoform not normally expressed in skeletal muscle (89).  While the 
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mechanism of this effect is unclear, the benefit of laminin-111 injections may be 
due to either upregulation of α7 integrin mediated signaling or integrin-mediated 
stabilization of the sarcolemma (89).  However, a transgenic approach to deliver 
laminin-111 to skeletal muscle failed to benefit mdx mice (90) despite its rescue 
of muscular dystrophy in laminin α2 deficient muscle (91, 92).  So while laminin 
α1 and α2 are normally expressed in different tissues, they appear to be 
functionally similar in promoting muscle cell survival.  Whether this important 
function of laminin in muscle can be targeted therapeutically in all forms of DGC 
deficient muscular dystrophy is still debatable.   
Integrins are formed as heterodimers of α and β subunits, and the 
predominant alpha isoform expressed in differentiated skeletal muscle, α7 
integrin, forms dimers with β1integrin to form a laminin receptor.  Mutations in α7 
integrin result in muscular dystrophy in patients and in animal models, and a loss 
of α7 integrin in muscle has been shown to predominantly affect the structure 
and function of the myotendinous junction, where α7β1 integrin is highly 
expressed (93-95).  α7β1 integrin is also expressed at costameres and, similar to 
α-dystroglycan, can associate intracellularly with cytoskeletal proteins and may 
contribute to mechanical stability of the sarcolemma (49).  Animals lacking both 
dystrophin and α7 integrin display a much more severe form of muscular 
dystrophy than animals lacking either protein alone, which suggests that both 
laminin receptors may be required at the sarcolemma and can potentially 
compensate for one another (96).  Transgenic overexpression of α7 integrin can 
partially alleviate muscle disease in dystrophin/utrophin double knock-out mice 
independently of any change in expression of DGC components (50, 97).  
However, integrins are associated with a number of signaling pathways and can 
alter AKT and MAP kinase activity in a contraction-dependent manner (98).  
Therefore, some of the improvement observed when integrins are overexpressed 
in dystrophic muscle may be in part due to changes in cell signaling rather than 
direct prevention of sarcolemma damage.   
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While the integrins may function as laminin-dependent signaling receptors 
in skeletal muscle (99), whether dystroglycan and the DGC may similarly 
participate in downstream signal transduction cascades is less clear.  Rather 
than simply serving as a membrane “stabilizer”, dystrophin has also been 
proposed to serve as a sensor for membrane tension and function early in the 
development of skeletal muscle (100).  The authors of this early study proposed 
that this function of the DGC may be achieved through either interactions with 
stretch-activated cation channels or through regulation of a downstream signaling 
mechanism analogous to integrin signaling.  Such signaling would likely be 
important for either growth of differentiated fibers or for mediating proliferation or 
fusion of satellite cells with regenerating fibers.  Interestingly, when the 
dystroglycan gene was specifically targeted in differentiated skeletal muscle 
using cre-loxP mediated recombination, the phenotype was surprisingly mild 
compared to other models of DGC related muscular dystrophy (101).  The 
residual expression of dystroglycan in satellite cells suggested that dystroglycan 
might have an unappreciated role in this cell type, which could be important for 
either cell signaling within satellite cells or for interactions with the basal lamina 
(101).  However, how the DGC may be functioning in muscle regeneration is not 
known. 
Given the critical role of laminin in promoting cell survival signaling in 
muscle and the existence of two possible receptors that might mediate its effects, 
dissecting the molecular mechanisms of each would certainly be a key advance 
towards understanding how disruptions can result in muscle disease.  A 
truncated form of laminin-α1 was recently generated that lacks LG domains 4-5 
and can prevent dystroglycan binding while retaining the LG domains necessary 
for laminin interactions with integrins.  In contrast to full length laminin-α1, when 
this truncated laminin-α1 was transgenically expressed in laminin-α2 deficient 
muscle, several fibers in select muscle groups were still apoptotic (102).  
Because transgenic expression of full length laminin-α1 can fully rescue the 
dy/dy phenotype, this suggests that interactions between dystroglycan and 
laminin are also important for cell survival signaling.  This is the first study to our 
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knowledge that directly implicates dystroglycan in laminin-dependent survival 
signaling in muscle in vivo and suggests that disruption of dystroglycan-
dependent signaling may also contribute to the pathology of muscular dystrophy. 
Several studies using primarily cell culture systems have shown that the 
DGC may be capable of participating as a scaffold for various signal transduction 
cascades (Fig. 1.2).  β-Dystroglycan is capable of binding multiple signaling and 
adaptor proteins known to be important for myoblast differentiation and cell 
survival signaling (103-106).  The c-terminus of  β-dystroglycan contains a 
proline rich region that can bind Grb2, a well known adaptor protein (103, 107) 
and may be important for recruiting additional components of the MAP kinase 
pathway (105).  Dystroglycan can also be phosphorylated at tyrosine892 near the 
c-terminus of β-DG (104, 108) and may function to regulate interactions between 
dystrophin and caveolin-3 (108, 109).  This phosphorylation has also been shown 
to be adhesion-dependent and enables dystroglycan to recruit several SH2-
domain containing proteins, including c-Src and Fyn, to the sarcolemma (110).  
In an unrelated study, these two kinases were also shown to be associated with 
the DGC and functioned to phosphorylate the DGC protein syntrophin (106).  In 
the presence of laminin, syntrophin was shown to associate with the DGC and 
mediate downstream Rac1 signaling that led to increased activity of c-jun.  This 
result was suggested to explain how increased doses of laminin in vitro led to a 
dose dependent increase in cell proliferation in C2C12 myoblasts (111).  An 
increase in Rac1 signaling was also observed following muscle contraction, 
which suggested that interactions between laminin and dystroglycan are 
important for enabling the DGC to function as a laminin-dependent 
mechanoreceptor (106).    
The PI3K/AKT pathway is an important signaling pathway essential for 
muscle cell survival, growth, and hypertrophy that has been suspected to 
function downstream of the DGC.  Disruption of laminin/dystroglycan binding in 
vitro by antibody blockade results in a decrease in PI3K mediated 
phosphorylation of AKT and is associated with an increase in apoptosis (112).  
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This result may be mediated in part through interactions of the DGC with 
heterotrimeric G-proteins, which has also been shown to be laminin-dependent.  
In the presence of laminin, dystroglycan can be immunopreciptated in a complex 
with Gβγ and PI3K and leads to an increase in AKT activation (113).  Therefore, 
the authors of this study concluded that, in muscular dystrophies where the DGC 
is disrupted, loss of an interaction with Gβγ can impair PI3K signaling and may 
contribute to disease pathology.  Several studies have demonstrated 
perturbations in AKT signaling in mdx muscle but generally have demonstrated 
an increase in AKT activity rather than a decrease that would be predicted by 
these cell culture studies (113, 114).  This potentially could be due to increased 
AKT signaling downstream of α7β1 integrin, which is upregulated in mdx muscle 
(115) and has been shown to be beneficial when overexpressed in dystrophic 
muscle either directly (116) or downstream of IGF-1 (117-119).   
While the potential loss of PI3K/AKT signaling downstream of laminin 
binding may impact muscle function through its effect on cell survival or growth, 
skeletal muscle function may also be compromised due to increases in activity of 
the ubiquitin-proteasome system (UPS)(120).  MuRF1 and MAFbx/atrogin-1 are 
important mediators of skeletal muscle atrophy that function to ubiquitinate target 
proteins which subsequently results in their destruction by the proteasome (120).  
In a recent study, decreased phosphorylation of AKT was demonstrated in 
laminin-deficient muscle and was associated with an increase in total amount of 
ubiquitinated protein (121).  Additionally, pharmacological inhibition of the 
ubiquitin-proteasome pathway in laminin-deficient animals resulted in an 
amelioration of several pathological features of the disease.  This led the authors 
to conclude that impaired laminin-dependent signaling in dystrophic muscle may 
also be impacting the UPS and contributing to muscle disease.  Although a 
number of signaling pathways are known to be important for skeletal muscle 
growth, the exact contributions of disrupted dystroglycan-dependent or integrin-
dependent signaling in dystrophic muscle still needs to be formally addressed.      
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Direct Role of the Dystrophin-Glycoprotein Complex in Force Transmission   
While muscle damage is hypothesized to be important in the pathogenesis 
and progression of DGC-associated muscular dystrophy, dystrophic muscle 
displays considerable muscle weakness even in very early stages of the disease.  
This weakness, expressed as a reduction in specific force normalized to the 
cross sectional area of the muscle, occurs prior to muscular atrophy and can 
even be measured in the presence of pseudohypertrophy in early phases of the 
disease (122, 123).  Our studies and the studies of others, in soleus muscle of 
DGC-deficient muscular dystrophies, demonstrate that the soleus muscle is also 
weak and this weakness is completely independent of an increased susceptibility 
of the muscle to damage (39, 48).  Therefore, muscle damage that results as a 
consequence of contraction-induced injury cannot fully explain the muscle 
weakness in DGC associated muscular dystrophy.  
Given the location of the DGC at costameres in muscle, several 
investigators have hypothesized that the DGC might contribute to “lateral 
transmission of force” from the sarcomere to the lateral extracellular matrix (15, 
124-126).  While the concept of longitudinal force generated in sarcomeres and 
transmitted down myofibrils in muscle to the tendon is well studied, the concept 
of lateral force transmission is less well appreciated.  This concept of lateral 
transmission of force in muscle was first described in frog muscle by Street in the 
early 1980’s (127).  In these studies, force was shown to be transmitted laterally 
from a single dissected fiber to the fibers flanking it in a muscle fiber bundle, with 
little or no decrement.  Formal proof that the DGC was important in lateral 
transmission of force in muscle was lacking.  Recently, we developed a novel 
yoke apparatus to directly measure the transmission of force from the muscle 
laterally to the extracellular matrix and the epimysium (128).  Applying this 
approach to mdx muscle, we showed for the first time that loss of DGC function 
in tibialis anterior muscles of mdx mice was sufficient to cause an approximately 
40% loss in lateral force transmission in the muscles.  While the precise 
contribution of each of the other components of the cytoskeleton, the costamere, 
and the extracellular matrix to the lateral transmission of force in muscle remains 
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to be elucidated, the loss of lateral transmission of force may help explain how 
loss of the DGC at the lateral membrane contributes muscle weakness and 
fragility.  Furthermore, the lateral transmission of force might be critical in 
transmitting force around the sites of focal myofiber injury in whole muscle and 
may help explain the markedly enhanced force deficits caused by lengthening 
contractions observed in fast muscles of DGC deficient animals (Fig. 1.3). 
DGC Function in Non-Muscle Tissues 
Although muscle dysfunction is the primary feature of mutations affecting 
DGC function, this protein complex is expressed in multiple cell types which 
highlight the potential for important non-mechanical functions of this complex.  
While the molecular composition of the DGC demonstrates significant 
heterogeneity within different cell types and cellular compartments, the presence 
of dystroglycan within the core of the complex appears critical.  Dystroglycan is 
an important contributor to the formation of basement membranes (23) and in 
many tissues, this function may be important for the attachment of epithelial cells 
to form structural barriers (129).  In dystroglycan-null brain, discontinuities in the 
glial limitans basement membrane are observed and this function of dystroglycan 
does not appear to require the C-terminal domain of β-DG which is responsible 
for interactions with dystrophin and the actin cytoskeleton (130, 131).  Within the 
brain, dystroglycan is expressed in migrating neurons as well as in radially 
oriented glia (132), and cell-specific targeted deletions of dystroglycan have 
delineated many of the distinct functions of dystroglycan within the different cell 
types.  While the absence of neuronal dystroglycan impaired long-term 
potentiation in the hippocampus, the layering of the cerebral cortex during 
development was unaffected (131).  This was in contrast to dystroglycan deletion 
in both glial and neuronal cells which resulted in laminar disorganization of the 
cerebral cortex and extensive neuronal/glial heterotopia.  Dystroglycan is also 
expressed in a specialized DGC in Schwann cells, the myelinating glia of the 
peripheral nervous system.  The gene-targeted deletion of dystroglycan in 
Schwann cells resulted in impaired nerve conduction, altered structure of the 
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nodes of Ranvier, and impaired localization of voltage-gated sodium channels 
(133).  Notably, these defects are similar to what has been observed in the 
dy2J/dy2J model of laminin deficiency (26, 134) which highlights the importance of 
interactions between dystroglycan and laminin in normal neural development.    
The DGC is also uniquely expressed at the neuromuscular junction and 
the initial identification of dystroglycan as an agrin receptor at the postsynaptic 
membrane suggested a critical function for the DGC in the assembly of 
neuromuscular junction (135-137).  However, acetylcholine receptor clustering 
during formation of the synapse can occur in the absence of interactions between 
dystroglycan and agrin (138, 139), and dystroglycan is suspected to have 
important functions in the maintenance of this structure in differentiated muscle 
via its function in basement membrane assembly (140). 
Glycosyltransferase-Deficient Muscular Dystrophy 
The important functions of dystroglycan are underscored by parallel 
defects observed in both patients with glycosyltransferase-deficient muscular 
dystrophy and animal models of these diseases.  These diseases share a 
common biochemical defect in the glycosylation of α-dystroglycan and 
consequently exhibit muscular dystrophy concomitant with a broad range of 
clinical symptoms in the CNS and PNS (141).  Similar to human patients with 
either Muscle-eye-brain disease (MEB) (142) or Fukuyama congenital muscle 
dystrophy (FCMD) (143), LARGEmyd animals also display abnormal neuronal 
migration and disorganized cortical layering in the brain as a consequence of 
impaired dystroglycan function.  Peripherally, LARGEmyd mice also demonstrate 
impaired structure of the NMJ (144), reduced nerve conduction velocity, and 
abnormal nerve myelination (145), defects shared in fukutin-deficient chimeric 
mice (146).    
Although the identification of mutations in glycosyltransferases has 
highlighted critical functions of dystroglycan and the DGC in non-muscle tissues, 
the precise mechanism by which impaired dystroglycan causes disease is 
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unclear.   Although mutations in these enzymes are rare, the identification of a 
shared biochemical defect and the increasing frequency of reports describing 
affected patients have led to an expansion in the spectrum of clinical 
observations.  Perhaps most notable of these diseases that result in a significant 
range of phenotypic severity are those associated with mutations in fukutin-
related protein (FKRP).  Mutations in FKRP can cause both congenital muscular 
dystrophy 1C (CMD1C) and a milder limb-girdle muscular dystrophy 2I (LGMD2I 
) both initially characterized by elevated serum creatine kinase, muscle 
weakness, hypotonia, and an absence of any brain involvement (147, 148).  
More recently, mutations in FKRP have also been identified in patients with 
severe mental retardation and cerebellar cysts (149).  Mutations that cause MEB 
and Walker-Warburg syndrome (WWS) have been identified in protein-O-
mannosyltransferase 1 (POMT1)(150), POMT2 (150, 151), and protein-O-
mannose β1,2-N-acetylglucosaminyltranferase (POMGnT) (142) and the broad 
clinical spectrum for each of these diseases have made it difficult to correlate 
gene mutations with disease manifestations (152).  While diseases like WWS, 
MEB, and FCMD were once thought to be distinct, the identification of a common 
genetic basis and the wide range of clinical  symptoms associated with each 
disorder has made it difficult to a determine distinct cellular functions of 
dystroglycan and thus, ways to prevent or delay the disease progression.  
Several mutations have now been identified in glycosyltransferases and 
presently, dystroglycan is the only known shared glycosylation target.  Therefore, 
a potential confounding variable that has made it difficult to attribute the 
pathologic features of these disorders to the impaired dystroglycan function is the 
potential existence of additional substrates (153, 154).  Moreover, the degree to 
which dystroglycan glycosylation is impaired in skeletal muscle is not a 
predictable indicator of disease severity or accompanying clinical symptoms 
(155).  
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Rationale and Experimental Approach 
Several studies have suggested that mutations affecting the DGC result in 
muscular dystrophy due to the importance of this complex in preserving 
sarcolemmal integrity.  While several reports have demonstrated deficits in force 
production in dystrophic muscle in response to contraction-induced damage, it is 
not clear whether these defects are directly due to changes in sarcolemma 
integrity.  Additionally, while it is clear that dystroglycan has important functions 
in development and function of striated muscle and the nervous system, how 
impaired function of dystroglycan as an extracellular matrix receptor contributes 
to glycosylation-deficient muscular dystrophy is poorly understood. 
The overall working hypothesis of this thesis is the following: LARGE-
mediated glycosylation is essential for normal skeletal muscle function, the 
complete loss of which results in muscular dystrophy due to the combined 
and specific effects on the function of dystroglycan in differentiated 
skeletal muscle, at the neuromuscular junction, and in motor neurons.  This 
hypothesis was tested with the following specific aims: 
Specific Aim 1). Determine whether the primary defect in LARGE-deficient 
muscular dystrophy is due to impaired interactions between the sarcolemma and 
the extracellular matrix which predisposes skeletal muscle to injury during muscle 
contraction. 
The purpose of this set of experiments, described in Chapter 2, was to 
investigate the functional defects in slow-twitch and fast-twitch muscles of 
glycosylation-deficient LARGEmyd mice.  While a partial alteration in glycosylation 
of dystroglycan in heterozygous Largemyd/- mice was not sufficient to alter muscle 
function, homozygous LARGEmyd/myd mice demonstrated a marked reduction in 
specific force in both soleus and extensor digitorum longus (EDL) muscles.  
Although EDL muscles from LARGEmyd/myd mice were highly susceptible to 
lengthening contraction-induced injury, LARGEmyd/myd soleus muscles surprisingly 
showed no greater force deficit compared with wild-type soleus muscles even 
after five lengthening contractions.  Despite the lack of increased susceptibility to 
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injury, LARGEmyd/myd soleus muscles showed loss of dystroglycan glycosylation 
and laminin binding activity and dystrophic pathology. Interestingly, soleus 
muscles have a markedly higher sarcolemma expression of β1-containing 
integrins compared with EDL and gastrocnemius muscles.  Therefore, β1-
containing integrins may play an important role as alternative matrix receptors in 
protecting muscles containing slow-twitch fibers from contraction-induced injury 
in the absence of dystroglycan function.   Additionally, this study demonstrates 
that contraction-induced injury appears to be a separable phenotype from the 
dystrophic pathology of muscular dystrophy. 
Specific Aim 2). Determine whether overexpression of LARGE in skeletal 
muscle is sufficient to enhance dystroglycan function and protect skeletal muscle 
from contraction-induced injury. 
To further determine the importance of dystroglycan glycosylation in 
skeletal muscle function, transgenic mice were generated that direct 
overexpression of LARGE specifically in differentiated muscle fibers.  I tested the 
hypothesis that overexpression of LARGE would result in enhanced dystroglycan 
glycosylation and function above that observed even in normal muscle.  These 
results, described in Chapter 3, demonstrate that hyperglycosylation of 
dystroglycan in skeletal muscle of MCK-LARGE transgenic mice coincided with a 
significantly elevated laminin binding affinity compared to that of wild-type 
muscles.  Additionally, fast-twitch skeletal muscle from transgenic mice 
demonstrated enhanced protection from contraction-induced injury such that 
force deficits following injury were significantly less when compared to muscle 
from wild-type mice.  This suggests that hyperglycosylation and enhanced 
function of dystroglycan via increased activity of the enzyme LARGE may be 
therapeutic not only in inherited glycosylation-deficient muscular dystrophy but 
also in acquired diseases or disability resulting from muscle injury. 
Specific Aim 3).  Determine how loss of LARGE-mediated glycosylation of 
dystroglycan in neural tissues contributes to muscle dysfunction and disease 
progression in LARGEmyd mice.  
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Although dystroglycan glycosylation is essential for normal skeletal muscle 
function, the nature of LARGE-mediated glycosylation of dystroglycan in non-
muscle tissues is unclear.  Dystroglycan is expressed ubiquitously in the brain 
and in the peripheral nervous system, but the specific mechanistic role of 
dystroglycan glycosylation in these tissues and how it affects muscle function 
and motor coordination has not been determined.  Chapter 4 describes 
experiments where MCK-LARGE transgenic animals were crossed to 
LARGEmyd/myd mice to produce animals that demonstrate impaired dystroglycan 
receptor function in all tissues except differentiated muscle fibers.  This resulted 
in the successful rescue of skeletal muscle function as evidenced by a reduction 
in serum creatine kinase, restoration of normal muscle structure, suppression of 
muscle degeneration, and an increase in both specific force and protection from 
contraction-induced injury.  Additionally, structural defects observed at the 
neuromuscular junction in LARGEmyd/myd mice were corrected in transgenic 
LARGEmyd/myd animals and correspondingly were associated with the rescue of 
the neurotransmission and nerve conduction deficits observed in LARGEmyd/myd 
animals.  These data suggest that skeletal muscle weakness observed in 
LARGEmyd/myd mice is the result of combined defects in both muscle and nerve 
function and that neuronal defects associated with impaired dystroglycan function 
may be compounded by primary deficits in muscle function that affect 
communication at the neuromuscular synapse. 
The final chapter will summarize the main findings of this thesis and 
describe how they have expanded upon what we previously knew about 
dystroglycan function.  Finally, this thesis will conclude with some of the 
remaining questions regarding dystroglycan function and how a complete 
understanding of both glycosylation dependent and independent functions of 
dystroglycan in various tissues where the DGC is expressed may be important 
for generating better therapeutics and potential cures for muscular dystrophy. 
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Figure 1-1) Sources of calcium entry in dystrophic muscle.  
(1) Disruptions to the DGC can result in instability of the sarcolemma that permits 
calcium entry through membrane tears when the sarcolemma is stretched during 
lengthening muscle contractions. (2) The activity of TRP and other stretch-
activated channels have been shown to be increased in dystrophin-deficient 
muscle and their inhibition in vivo can improve dystrophic pathology. (3) The 
ryanodine receptor has recently been shown to be hypernitrosylated in mdx 
muscle which may result in an increased leak of calcium from the sarcoplasmic 
reticulum.  
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Figure 1-2) Potential signaling pathways disrupted in muscular dystrophy.   
The dystrophin-glycoprotein complex may participate in laminin-dependent 
signaling in skeletal muscle.  Interactions shown in blue indicate interactions that 
have been shown to be increased when laminin is bound to dystroglycan.  
Interactions in pink indicate those that have been shown to be increased 
following a muscle contraction protocol.  Since the phosphorylation of β-
dystroglycan can bind a number of other SH2-domain containing proteins and 
can also interact with Grb2, it may participate in additional signal transduction 
cascades that have not yet been identified.  It is important to remember that in 
many cases, these interactions have been studied in cell culture systems and the 
relevance of these interactions in muscle in vivo has not been extensively 
characterized. 
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Figure 1-3) Lateral force transmission in skeletal muscle.  
The dystrophin-glycoprotein complex transmits forces laterally at costameres in 
muscle.  Longitudinal forces generated in sarcomeres are transmitted down 
myofibrils in muscle, and forces are also transmitted laterally to the ECM and 
neighboring muscle fibers at costameres, at least in part through the dystrophin-
glycoprotein complex (DGC).  Recent data showing a loss of lateral force 
transmission in dystrophin-deficient muscle explains how the reduction or 
improper assembly of the DGC at the lateral membrane may contribute to overall 
muscle weakness and fragility. 
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CHAPTER 2 
 
Soleus muscle in glycosylation-deficient muscular dystrophy is protected 
from contraction-induced injury 
 
ABSTRACT 
The glycosylation of dystroglycan is required for its function as a high affinity 
laminin receptor, and loss of dystroglycan glycosylation results in congenital 
muscular dystrophy.  The purpose of this study was to investigate the functional 
defects in slow and fast muscles of glycosylation-deficient LARGEmyd mice.  
While a partial alteration in glycosylation of dystroglycan in heterozygous 
LARGEmyd/+ mice was not sufficient to alter muscle function, homozygous 
LARGEmyd/myd mice demonstrated a marked reduction in specific force in both 
soleus and EDL muscles.  Although EDL muscles from LARGEmyd/myd mice were 
highly susceptible to lengthening contraction-induced injury, LARGEmyd/myd soleus 
muscles surprisingly showed no greater force deficit than wild-type soleus 
muscles even after 5 lengthening contractions.  Despite no increased 
susceptibility to injury, LARGEmyd/myd soleus muscles showed loss of dystroglycan 
glycosylation and laminin binding activity, and dystrophic pathology.  
Interestingly, we show that soleus muscles have a markedly higher sarcolemma 
expression of β1 containing integrins compared with EDL and gastrocnemius 
muscles.  Therefore, we conclude that β1 containing integrins play an important 
role as matrix receptors in protecting muscles containing slow-twitch fibers from 
contraction-induced injury in the absence of dystroglycan function, and that 
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contraction-induced injury appears to be a separable phenotype from the 
dystrophic pathology of muscular dystrophy.  
INTRODUCTION 
The muscular dystrophies comprise a heterogeneous group of genetic 
diseases characterized by progressive degeneration of myofibers, severe 
weakness, and impaired skeletal muscle function (2).  Although these diseases 
can arise from a single mutation in any of several known causative genes, a 
subset of congenital muscular dystrophies known as the “dystroglycanopathies” 
are caused by distinct mutations that result in loss of function of the membrane 
protein, dystroglycan, as an extracellular matrix receptor (156).  Mutations have 
been identified in several genes that appear to encode glycosyltransferases 
(157).  While specific glycan structures have been proposed to be important for 
the function of dystroglycan as an extracellular matrix receptor (158), the precise 
pathway by which each of these glycosyltransferases functions is unclear.  In 
each of the dystroglycanopathies, the glycosylation of dystroglycan is reduced or 
lost completely (21).  The reduction or loss of the glycosylation of dystroglycan 
impairs the function dystroglycan, which is thought to lead to the observed 
phenotypes in the many tissues where dystroglycan is expressed. 
Dystroglycan is transcribed from the DAG1 gene and the protein is 
cleaved post-translationally into α and β subunits (159) which then remain 
associated with one another at the cell membrane (160).  The β-dystroglycan (β-
DG) subunit contains a single transmembrane domain and associates with 
dystrophin at its intracellular C-terminus.  In contrast, the extracellular α-DG 
subunit localizes to the exterior of the sarcolemma due to its non-covalent 
association with β-DG.  The extensive glycosylation enables α-DG to function as 
a receptor for several ligands in the extracellular matrix (ECM) that include 
laminin, agrin, & perlecan (12, 137, 161).  The interaction of α-DG with laminin 
appears to be critical for the normal functioning of skeletal muscles in that both 
reduction of α-DG glycosylation leading to loss of laminin binding affinity, and null 
mutations in laminin α2, leading to loss of the predominant laminin expressed in 
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skeletal muscle, result in severe congenital muscular dystrophy (21, 27).  
Dystroglycan is an essential component of the dystrophin-glycoprotein complex 
(DGC) in muscle, a multi- subunit complex that links the intracellular actin 
cytoskeleton to the extracellular matrix (ECM) through the interactions of β-DG 
with dystrophin and α-DG with the ECM (162, 163).  Null mutations in several 
components of the DGC, including dystrophin, that disrupt DGC expression also 
cause several forms of muscular dystrophy in humans.    
While the complete function of the DGC in muscle is unknown, 
dystroglycan is hypothesized to provide a mechanical link that helps maintain 
integrity of the sarcolemma during cycles of contraction and relaxation (12).  
Evidence that the DGC plays a role in stabilizing the sarcolemma during 
contraction comes from observations that dystrophic muscle, with genetic 
disruption of the DGC, is highly susceptible to contraction-induced injury (164).  
The mdx mouse contains a null mutation in dystrophin, and mdx muscle 
demonstrates an increased propensity for muscle injury as measured by a 
significantly elevated force deficit when maximal force production is measured 
before and after a series of lengthening contractions (39).  Additionally, increased 
force deficit in mdx muscle following injury is associated with an increase in 
membrane permeability when lengthening contractions are performed in the 
presence of a membrane impermeant dye (165).  Such defects at the membrane 
are thought to either directly or indirectly contribute to the observed degeneration 
of myofibers that ultimately results in impaired muscle function and weakness.   
The increased fragility of the sarcolemma in mdx mice is also supported by the 
observation that treatment with membrane sealants in vitro leads to a decrease 
in the magnitude of injury produced by repetitive isometric contractions (166).  
Therefore, susceptibility to contraction-induced injury appears to be a hallmark 
feature in many forms of DGC-related muscular dystrophy.  Although the 
presence of dystroglycan is hypothesized to be essential for normal function of 
the DGC, the role of dystroglycan glycosylation which specifically regulates its 
function as a matrix receptor in the preservation of sarcolemma integrity during 
lengthening contractions is not as well defined.  Therefore, our goal was to study 
32 
 
the functional deficits in a mouse model of glycosylation-deficient muscular 
dystrophy to provide further insights into the role of the interaction of 
dystroglycan with the ECM in skeletal muscle function. 
The LARGEmyd mouse is a spontaneously arising mouse model of 
muscular dystrophy that contains an autosomal recessive mutation in the gene 
that encodes the glycosyltransferase LARGE and consequently demonstrates 
reduced glycosylation of α-dystroglycan (167, 168).  Although enzymatic activity 
for LARGE has not been confirmed, it contains two predicted catalytic domains 
(167) and has been shown to directly bind to the N-terminus of dystroglycan 
(169).  Additionally, overexpression of LARGE in myoblasts from patients with 
defects in other glycosyltransferases restores dystroglycan function (170).  
Although several studies have identified specific glycan structures that may be 
necessary for dystroglycan function (171-174), the precise glycan on 
dystroglycan that is transferred by LARGE and its role in normal skeletal muscle 
function is presently unknown.  
While mice provide important genetic models of human disease, the 
composition of fiber types in muscles of humans and mice differ significantly.  
The limb muscles most commonly studied in dystrophic mice, the extensor 
digitorum longus and tibialis antierior, are composed almost exclusively of fast-
twitch fibers with an approximately equal proportion of glycolytic and oxidative 
fibers.  However, the soleus muscle is one of the few skeletal muscles in the 
mouse that contains a large percentage of slow fibers (>50% of the total) (175).  
In that regard it is interesting to note that many human skeletal muscles involved 
in locomotion are similarly composed of a mixture of both fast-twitch and slow-
twitch fiber types.  Mouse soleus muscle was also shown to bear a greater 
molecular resemblance to human muscle and was therefore more representative 
of human muscle than other commonly studied mouse muscles such as the EDL 
and gastrocnemius muscle which are composed of predominantly fast-twitch 
fibers (176).  Muscle fiber types are determined by activation of distinct genetic 
programs that regulate both myosin isoform composition and oxidative capacity.  
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Whether the complex glycosylation pathway necessary for dystroglycan 
glycosylation and function, or the impact of the loss of its function is similar in 
both fast and slow muscle fiber types is not known.  Therefore, we compared the 
contractile defects associated with loss of LARGE-dependent glycosylation of 
dystroglycan in fast and slow muscles.  In doing so, we identified differences in 
expression of key matrix receptors between fast-twitch and slow-twitch fibers that 
might underlie fiber type specific differences in the susceptibility to contraction-
induced injury of the skeletal muscles of the dystrophic LARGEmyd mouse.   
Furthermore, while susceptibility to contraction-induced injury is often considered 
a hallmark of DGC related muscular dystrophies, our data shows that dystrophic 
pathology and muscle weakness is a clearly separable phenotype from 
contraction-induced injury in muscles containing a mixture of fast and slow 
muscle fibers.   
METHODS 
Animals. All animals were housed in a specific pathogen free (SPF) barrier 
facility in the Unit for Laboratory Animal Medicine at the University of Michigan, 
and all procedures were approved by the University of Michigan Committee for 
the Use and Care of Animals.  LARGEmyd and WT littermates used for all 
experiments were aged 12-36 weeks and taken from a maintained colony.  
Sprague-Dawley rats were received from Charles River Laboratory.  
Measurement of Contractile Properties. Contractile measurements were 
performed as previously described (177).  For in vitro measurements, the EDL or 
soleus muscle was isolated from anesthetized mice.  A 5-0 silk suture was tied to 
the proximal and distal tendons. The muscle was placed in Krebs mammalian 
Ringer solution maintained at 25°C and bubbled continuously with  95% O2 and 
5% CO2 to stabilize pH at 7.4. One tendon was tied to a servo motor (Aurora 
Scientific, model 300) and the other to a force transducer (Kulite Semiconductor, 
model BG-50).  The muscle was stimulated by square wave pulses delivered 
between two platinum electrodes connected to a high-power biphasic current 
stimulator (Aurora Scientific, model 701B).  An IBM–compatible personal 
34 
 
computer and custom-designed software (LabVIEW 7.1, National Instruments, 
Austin, TX) controlled electrical pulse properties and servomotor activity and 
recorded data from the force transducer.  The voltage of pulses was increased, 
and optimal muscle length (Lo) was subsequently adjusted to the length that 
resulted in maximum twitch force (Brooks and Faulkner, 1988).  The Lo was 
measured with digital calipers.  Muscles were held at Lo and subjected to trains 
of pulses to generate an isometric contraction.  Pulse trains were 300 ms for EDL 
muscles and 900 ms for soleus muscles.  Stimulus frequency was increased until 
maximum isometric force (Po) was achieved (Brooks and Faulkner, 1988).  The 
muscle was weighed and the mean cross sectional area was estimated by 
dividing the muscle wet mass by the product of fiber length and the density of 
mammalian muscle 1.06g/cm3.  Specific force (sPo) was determined by dividing 
Po by the cross-sectional area (CSA). 
Muscle Injury Protocol. Following measurement of maximum twitch force and 
Po, muscles were stimulated and held at Lo for 100 ms for EDL muscles and 
300ms for soleus muscles to allow muscles to develop Po.  Following the 
isometric contraction, muscles were stretched through a 30% strain relative to Lf.  
The velocity of the stretch was 1 Lf/s.  The total time of stimulation was 400 ms 
for EDL muscles and 600 ms for soleus muscles.  Following stimulation, muscles 
were returned to Lo, then were subjected to four additional 30% stretches, each 
with 12 seconds in between, for a total of 5 stretches per muscle.  The muscle 
was allowed to rest one minute and Po was measured. The force deficit was 
calculated as the decrease in Po observed after the stretch protocol as a 
percentage of Po prior to the protocol.   
Membrane Preparation, SDS-PAGE, and Western Blotting. Mouse and rat 
EDL and soleus muscles were dissected from anesthetized animals, the 
myotendinous regions were removed, and samples were immediately frozen on 
dry ice until further processing.  Individual (rat) or pooled (mouse) samples were 
homogenized in ice-cold homogenization buffer containing 20 mM sodium 
pyrophosphate, 20 mM sodium phosphate (monobasic), 1 mM magnesium 
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chloride, 0.303 M sucrose, 5 mM EDTA, pH 7.1.  Samples were subjected to a 
low speed (10,000 g) and high speed (45,000 g) spin in order to isolate the 
membrane fraction and final pellets were resuspended in Buffer I (0.303 M 
sucrose, 20 mM Tris-Maleate, pH 7.0) and quantified using the Biorad Bradford 
assay.  All buffers contained protease inhibitors (0.5 µg/ml Pepstatin A, 2 
kallikrein inhibitor units/ml Aprotinin, 1 ug/ml Leupeptin, 0.4 mM PMSF, 0.6 mM 
Benzamidine).  Samples were separated using 3-15% gradient polyacrylamide 
gels and were transferred via Western blot to polyvinylidene fluoride membrane 
(Millipore).  After blocking membranes in TBS + 0.05% Tween 20 (TBS-T) + 5% 
non-fat dry milk for 1 hour, membranes were incubated with primary antibody for 
at least 2 hours up to overnight.  Primary antibodies included rabbit polyclonal 
antibodies to β-dystroglycan and α7 integrin (H40) (Santa Cruz),  α5 integrin and 
β1 integrin (Chemicon/Millipore), laminin (L-9393, Sigma), mouse monoclonal 
antibody to dysferlin (Hamlet, Novacastra), slow myosin (A4.840, DSHB, Iowa 
City, IA), and glycosylated dystroglycan (IIH6, gift from Dr. Kevin Campbell), rat 
monoclonal antibodies to α6 integrin (eBiosciences) and β1 integrin (BD 
Pharmingen).  Following 3 x 10 minute washes in TBS-T, membranes were 
incubated with secondary antibody conjugated to HRP for 1.5 hours.  
Membranes were washed 3 x 10 minutes with TBS-T and incubated in 
chemiluminescent substrate (Thermo Scientific) 1-2 minutes prior to exposure.  
Membranes used for re-probing were washed in TBS and incubated in a stripping 
buffer (TBS + 2% SDS + 7ul/ml β-mercaptoethanol) for 30 minutes. Membranes 
were rinsed several times in TBS and were re-blocked for 1-2 hours in TBS-T + 
5% NFDM prior to a second round of antibody staining.   
Solid-Phase Laminin Binding Assays. WGA-purified skeletal muscle samples 
were diluted in TBS and coated onto 96-well microplates at a final concentration 
of 0.1ug/well overnight.  After washing in binding buffer (TBS + Ca2+), plates 
were coated with a blocking buffer of 3% bovine serum albumin (BSA) in binding 
buffer for 1 hour.  Wells were aspirated, rinsed in binding buffer, and replaced 
with dilutions of 0.02 - 20 nM laminin (Invitrogen) and diluted in blocking buffer 
with and without the presence of 20 mM EDTA for 2 hours.  After 4 washes in 
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binding buffer, wells were replaced with anti-laminin antibody (L-9393) diluted 
1:5000 in blocking buffer and incubated at room temperature for 1.5 hours.  Wells 
were aspirated, washed 4 times in binding buffer, and replaced with goat anti-
rabbit IgG HRP diluted 1:5000 in blocking buffer for 1 hour at room temperature.  
Again, plates were washed 4 times in binding buffer.  For developing, 100ul of 
OPD/CPB was added to each well and incubated 5-25 minutes. The reaction was 
stopped with 50ul 2M H2SO4 and plates were read at 495nm. 
Immunofluorescence & Histology. Soleus, EDL, and gastrocnemius muscles 
were dissected together from anesthetized mice, mounted in OCT and 
immediately frozen in liquid nitrogen cooled isopentane.  Frozen samples were 
cut into 8 µm cross sections using a cryostat and stored at -80° until the slides 
were later used for immunofluorescent microscopy or stained with either 
hematoxylin and eosin or 0.1% Sirius Red/0.1% Fast Green in picric acid.  For 
immunohistochemical experiments, slides were rehydrated with PBS and blocked 
1-2 hours in 5% BSA in PBS.  Slides were then incubated with primary and 
secondary antibody for 1-2 hours each with 4 x 5 minutes washes of PBS in 
between incubations.  Final slides were mounted in Permafluor (Invitrogen) and 
imaged with an Olympus BX-51 fluorescence microscope.    
RESULTS 
Partial loss of dystroglycan glycosylation in heterozygous LARGEmyd/+ 
mice.  Homozygous LARGEmyd/myd mice have previously been described as 
having a complete loss of alpha dystroglycan glycosylation as demonstrated by 
the loss of reactivity with the glycosylation specific antibody IIH6 (21).  Western 
blot analysis from skeletal muscle whole lysates (WT, LARGEmyd/+, and 
LARGEmyd/myd) revealed altered glycosylation in mice heterozygous for the 
LARGE mutation as indicated by a slight reduction in the molecular weight of α-
dystroglycan (Fig. 2.1A).  Partial loss of α-dystroglycan glycosylation has also 
been detected in human patients with mild limb-girdle muscular dystrophy (156).  
Although heterozygous LARGEmyd/+ mice did not show pathology consistent with 
muscular dystrophy (Fig. 2.1B, Fig. 2.6), the potential functional effects of the 
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partial glycosylation of dystroglycan remain unknown.  Therefore, the contractile 
function of heterozygous mice was studied to determine whether the altered 
glycosylation due to the presence of a single functional LARGE gene was 
sufficient to cause changes in skeletal muscle function.  Although absolute and 
specific forces were both reduced in the soleus and EDL muscles of homozygous 
LARGEmyd/myd mice, heterozygous mice exhibited no significant differences when 
compared to wild-type littermates (Fig. 2.2A, B).  In response to muscle injury 
induced by two lengthening contractions of 30% strain, force deficits measured in 
heterozygous mice displayed no differences from WT mice for either the EDL 
muscle (17%, WT; 18%, heterozygous) or the soleus muscle (22%, WT; 21% 
heterozygous) (Fig. 2.2C).  Therefore, while the loss of a single functional 
LARGE gene was sufficient to reduce the glycosylation of dystroglycan in 
skeletal muscle slightly, this alteration was not sufficient to cause a change in 
muscle function or susceptibility to contraction-induced injury following 
lengthening contractions.   
Effects of complete loss of functional dystroglycan glycosylation on 
muscle function are fiber-type specific.  The complete loss of dystroglycan 
glycosylation in LARGEmyd/myd mice leads to dystrophic pathology (Fig. 2.1B, Fig. 
2.6), and results in a profound reduction in both absolute and specific force 
production (Fig. 2.2A, B).  The maximum specific force measured for muscles 
from homozygous LARGEmyd/myd mice was only 67% of that measured in EDL 
muscle and 66% of that measured in soleus muscle of WT mice indicating that 
maximal force production in skeletal muscle requires the presence of LARGE-
mediated glycosylation of dystroglycan.  Additionally, a significantly elevated 
force deficit of 36% was measured in the EDL muscle of homozygous 
LARGEmyd/myd mice after two lengthening contractions which was nearly 2-fold 
greater than the force deficit observed in EDL muscles from WT and 
heterozygous mice (Fig. 2.2C).  Interestingly, the degree of injury due to 
lengthening contractions in muscles containing functionally impaired dystroglycan 
seemed to be fiber type specific.  A force deficit of 22% measured in the soleus 
muscle of homozygous LARGEmyd/myd mice following two lengthening 
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contractions was not significantly different from that of WT mice.  To further 
stress the muscle we performed three additional lengthening contractions and 
after a total of five lengthening contractions, force deficits measured in EDL 
muscles from WT and heterozygous mice were not significantly different (35%, 
WT; 36%, heterozygous) nor were those in soleus muscles (26%, WT; 30%, 
heterozygous) (Fig. 2.2D).  While EDL muscles from homozygous LARGEmyd/myd 
mice showed a further increase in force deficit to 88% (compared to 32% in WT), 
the 30% force deficit measured in the soleus of LARGEmyd/myd mice after five 
lengthening contractions was still not significantly different from WT 
measurements.  These results suggest that while the complete loss of functional 
glycosylation of dystroglycan in LARGEmyd/myd skeletal muscle results in reduced 
maximal force production in both soleus and EDL muscle, the soleus muscle of 
LARGEmyd/myd mice is protected completely from the high degree of susceptibility 
to lengthening contraction-induced injury observed in the EDL muscle.  
LARGEmyd/myd soleus is dystrophic and demonstrates reduced 
glycosylation of dystroglycan concomitant with a reduction in laminin 
binding activity.  Because susceptibility to contraction-induced injury in skeletal 
muscle is considered to be a hallmark of DGC-related muscular dystrophies, we 
sought to determine whether the soleus of LARGEmyd/myd mice was also protected 
from dystrophy.  Hematoxylin and eosin staining of gastrocnemius, EDL, and 
soleus sections of LARGEmyd/myd mice revealed that similar to gastrocnemius and 
EDL muscles, the soleus contained several features of muscular dystrophy 
including a high percentage of fibers with internalized nuclei, heterogeneity in 
fiber size, and infiltration of mononuclear cells (Fig. 2.1B).   Additionally, all three 
muscles isolated from LARGEmyd/myd animals contained increased Sirus Red 
staining indicative of interstitial fibrosis (Fig. 2.6).  
An alternative hypothesis for the lack of susceptibility to contraction-
induced injury in the soleus muscle of LARGEmyd/myd animals was that perhaps a 
partial glycosylation of dystroglycan is preserved in soleus muscle through the 
actions of either the LARGE homologue, LARGE2, or alternative 
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glycosyltransferases (178).  In support of this hypothesis, we observed that 
although α-dystroglycan isolated from membrane preparations of rat EDL and 
soleus muscles ran as a broad smear, the range in the molecular weight of α-
dystroglycan was different between the two muscles (Fig. 2.4A).  Since the 
soleus muscle in the rat is composed almost exclusively of slow muscle fibers, 
this suggests potential fiber-type specific differences in glycosylation of 
dystroglycan.  However, immunofluorescent staining of LARGEmyd/myd soleus and 
gastrocnemius muscles confirmed that although dystroglycan is retained at the 
sarcolemma of fibers in the soleus, the functional glycosylation of α-dystroglycan, 
as indicated by reactivity with IIH6, was lost completely (Fig. 2.3A).  Despite the 
loss of glycosylated dystroglycan in the soleus, laminin was still detected at 
comparable levels in the ECM.  Using WGA-purified glycoproteins isolated from 
dissected muscles, we also show that soleus muscles from LARGEmyd/myd 
homozygous mice have markedly reduced high-affinity laminin binding activity 
similar to glycoprotein preparations isolated from EDL muscles (Fig. 2.3B) and 
gastrocnemius (not shown), and similar to what has been previously reported in 
pooled hindlimb muscles from LARGEmyd/myd mice (21).  Similar reductions in 
high affinity laminin binding activity are also observed in dystroglycan gene-
targeted mice demonstrating that this high affinity activity reflects dystroglycan-
dependent activity (101).  Together, these results demonstrate that the protection 
of the soleus muscle from contraction-induced injury in LARGEmyd/myd mice is not 
due to residual dystroglycan glycosylation and function.  Therefore, additional 
experiments were aimed at determining whether there were differences in 
expression of other laminin receptors between the two muscle types that might 
contribute to the protection from contraction-induced injury in soleus muscles of 
LARGEmyd/myd mice.  
β1 containing integrins are highly expressed in the sarcolemma of soleus 
muscles.  Integrins, which exist as dimers of alpha and beta subunits, are ECM 
receptors that are expressed in multiple tissues (179).  The α7β1 integrin is a 
laminin receptor expressed in skeletal muscle and loss of α7 integrin expression 
has been associated with impaired muscle function and myopathic diseases in 
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mouse models and in human patients (49).  To overcome the limitation in size of 
mouse EDL and soleus muscles and the need for high amounts of tissue in order 
to isolate sufficient quantities of membrane preparations, we first utilized muscle 
from the rat.  Because the soleus muscle of the rat is almost exclusively 
composed of slow muscle fibers compared to the mouse which is approximately 
50-60% slow fibers, this offered a higher contrast in fiber type distribution when 
comparing the soleus muscles to the EDL muscles and more easily allowed us to 
determine fiber type specific expression of several proteins involved in 
sarcolemma integrity.  In order to identify the alternative extracellular receptors 
that are expressed primarily at the lateral membrane, the tendons and 
myotendinous regions of the muscle were trimmed away.  In rat, membrane 
associated β1 integrin expression was markedly higher in soleus than EDL 
muscle (Fig. 2.4A).  We also examined the expression of dysferlin, a protein 
involved in membrane repair and associated with limb-girdle muscular dystrophy 
but did not see a difference in its expression between EDL and soleus muscle in 
either the rat (Fig. 2.4A) or the mouse (not shown).  Consistent with these results 
in rat muscle, separately pooled soleus and EDL muscle from mice also 
demonstrated a much higher expression of β1 integrin in the soleus than in the 
EDL muscle (Fig. 2.4B).  Additionally, immunofluorescence microscopy 
performed on gastrocnemius, soleus, and EDL muscle sections from mice 
demonstrated a higher degree of staining for β1 integrin at the sarcolemma in 
soleus muscle fibers compared to fibers in the gastrocnemius and EDL muscle 
(Fig. 2.4C, D).     
In skeletal muscle, the function of β1 integrin changes during development 
due to differential pairing with distinct alpha integrin isoforms.  During 
development, β1 integrin dimerizes with α5 integrin to form a receptor for 
fibronectin.  However, in adult muscle, α5 integrin expression is down-regulated 
and replaced with α7 integrin which, when dimerized with β1 integrin, forms a 
laminin receptor that is predominantly localized to the myotendinous junction 
(180).  Using both a WGA-purified fraction (Fig. 2.5A) and a microsome fraction 
(Fig. 2.5B) isolated from EDL and soleus muscles of rats, a heavy chain specific 
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α7 integrin antibody detected bands at both 100 kDa and 120 kDa.  The 120 kDa 
isoform is reported to be a glycosylated form of α7 integrin (181) and in support 
of this conclusion, only this isoform was detected in the WGA-purified fraction.  
While no differences were observed in expression levels of the 100 kDa α7 
integrin isoform in microsome fractions from either EDL or soleus, α7 integrin 
detected in the WGA-purified fraction appeared to be more highly expressed in 
soleus muscle.  Additionally, immunofluorescent staining detected α7 integrin 
expression predominantly at the sarcolemma in soleus in a pattern consistent 
with previously shown β1 expression (Fig. 2.4C, 2.5C).  To determine whether it 
may be possible that β1 integrin combines with other alpha integrins in the soleus 
to form receptors for additional extracellular ligands, Western blots and/or 
soleus/gastrocnemius muscle cross sections were also stained for α5 and α6 
integrin.  The α6 integrin was not expressed at detectable levels in either fibers of 
the soleus or gastrocnemius of WT muscle and instead appeared to be 
concentrated only in blood vessels (not shown).  The α5 integrin appeared to be 
expressed in both the EDL and soleus muscles but levels were lower than those 
in neonatal muscles and did not differ between the two muscle types (Fig. 2.5A). 
DISCUSSION 
 Our results demonstrate for the first time that, although the skeletal 
muscles of LARGEmyd/myd mice are weaker than WT controls, the soleus is 
protected from contraction-induced injury despite the loss of the glycosylation 
dependent function of dystroglycan as an extracellular matrix receptor.  We also 
show that soleus muscle has markedly higher expression of β1 integrin 
compared to other limb muscles composed of fast muscle fibers.  This 
observation suggests that α7β1 integrin may be playing an important role as an 
alternative matrix receptor capable of protecting the sarcolemma from 
contraction-induced injury in slow muscle.  Finally, although susceptibility to 
contraction-induced injury is often considered a hallmark of DGC-related 
muscular dystrophies, our results indicate that a susceptibility to contraction-
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induced injury is not required, and that muscle weakness and dystrophy can 
occur in the soleus of LARGEmyd/myd homozygous mice in its absence.  
 The exact mechanism by which the DGC protects muscle from injury 
following lengthening contractions and the relationship of muscle injury to the 
development of dystrophy is still unclear.  In whole muscle, lengthening 
contractions may produce injury by straining sarcomeres with pre-existing 
heterogeneity in length within muscle fibers, or strain lateral connections from 
fiber to fiber resulting in fiber damage and damage to sarcomeres (182).  
Alternatively, lengthening contractions may impart large mechanical strain on 
connections of muscle fibers to the matrix, disrupting those connections that 
stabilize the sarcolemma.  Recently, Han et al. demonstrated that dystroglycan is 
important for enabling skeletal muscle fibers to bind the sarcolemma tightly to the 
basal lamina, the loss of which results in muscle that is prone to contraction-
induced sarcolemma injury (22).  However, our results show that this is not 
universally true for all muscles.  The loss of glycosylation and function of 
dystroglycan is not sufficient to result in increased susceptibility to contraction-
induced injury in LARGEmyd/myd soleus muscle.  Interestingly, the soleus muscles 
of LARGEmyd/myd mice still have pathological features of muscular dystrophy 
including increased variability of fiber size and centrally nucleated fibers 
consistent with ongoing muscle degeneration and regeneration.  The soleus 
showed marked deficits in specific force and contained dystroglycan that lacked 
functional glycosylation and was unable to bind extracellular laminin.  This 
implies that contraction-induced injury is not a primary cause for dystrophy and 
weakness observed in this muscle.  While dystroglycan may have an important 
role in mechanically stabilizing fast-twitch muscle against contraction-induced 
injury, our results suggest that dystroglycan may also have additional essential 
functions in muscle that when impaired significantly contribute to the dystrophic 
phenotype and weakness in muscles containing slow-twitch fibers.   
Several groups have hypothesized that defects in cell signaling might 
contribute to the dystrophic pathology but the physiological significance has not 
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been demonstrated.  Muscles isolated from laminin-211 deficient dy/dy mice are 
dystrophic and weak but have been shown to be no more susceptible to 
contraction-induced injury when compared to wild-type animals (51).  Dy/dy 
animals have increased activation of apoptotic death pathways and it was 
suggested that altered signaling may contribute to the dystrophic pathology in 
laminin-211 deficiency (84, 87).  Consistent with this hypothesis, several studies 
have demonstrated that defects in the specific interaction of laminin with 
dystroglycan results in altered cellular signaling important for normal cell growth.  
The disruption of the laminin/dystroglycan interaction in vitro using blocking 
antibodies against α-dystroglycan resulted in altered AKT and GSK-3β activation 
and an increase in apoptotic cell death (112).  More recently, the DGC has also 
been shown to interact with subunits of heterotrimeric G proteins in a laminin 
dependent manner (113) which has been suggested to underlie the altered Ca2+ 
homeostasis observed in several forms of muscular dystrophy.  While the precise 
mechanism by which defects in dystroglycan result in impaired signaling is 
unclear, our results suggest that such signaling may be physiologically relevant 
and may have significant implications for other dystrophies associated with 
genetic disruption of the DGC that lead to a concomitant reduction in 
dystroglycan expression at the sarcolemma.   
Previous studies have shown that lengthening contractions of soleus 
muscles of mdx mice fail to cause higher force deficits or sarcolemma damage 
when compared to WT mice (36).  While this has led to the predominant use of 
muscles composed primarily of fast fibers such as EDL in studying contraction 
induced injury in the mdx mouse,  an underlying molecular mechanism that 
accounts for the lack of increased contraction-induced injury in soleus muscle 
has not yet been elucidated.  Muscle impairment due to the loss of dystrophin 
expression in mdx mice can be compensated by the upregulation of utrophin and 
differences in utrophin expression might be a reasonable hypothesis to explain 
the lack of susceptibility of the mdx soleus muscles to contraction-induced injury.  
However, in the present study, the LARGEmyd/myd sarcolemma contains normal 
expression of all DGC components including dystrophin and only the post-
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translational processing of α-dystroglycan and its laminin binding activity is 
compromised (22).  Therefore, we hypothesized that differences in expression of 
other extracellular matrix receptors between the EDL and soleus muscles may be 
responsible for the protection against contraction-induced injury.  In addition to 
dystroglycan, α7β1 integrin has also been shown to be an important laminin 
receptor essential for normal skeletal muscle function and mutations have been 
associated with muscular dystrophy in patients (93) and in animal models.  
Although the β1 integrin knockout mouse is embryonically lethal due to its 
essential role in embryogenesis (183, 184), the tissue specific loss of α7 integrin 
in skeletal muscle results in myopathy and initial experiments demonstrated that 
α7 integrin-deficient animals exhibited a myopathy predominantly affecting the 
myotendinous junction (94).  While most of the α7 integrin null skeletal muscle 
evaluated exhibited very few histological characteristics of muscular dystrophy, 
the authors noted that only the soleus showed histological signs of myopathy.  
These results support our observation that the α7β1 receptor, being more highly 
expressed in soleus, functions as an important laminin receptor along the lateral 
membrane of skeletal muscle fibers that can function in the prevention of 
contraction-induced injury specifically in slow-twitch fibers.   
Han et al. recently showed that loss of either the DGC or α7β1 integrin 
can result in deficits in force production but that only the loss of the DGC resulted 
in susceptibility to contraction-induced injury (22).  This was based on the 
observation that although a greater force deficit was observed in EDL muscles 
taken from LARGEmyd/myd animals when compared to WT controls, no such 
difference existed in EDL muscles from α7 integrin-null animals.  Although the 
soleus was not studied in these experiments, based on our results we would 
hypothesize that α7 integrin-null mice would indeed have a measured force 
deficit following contraction-induced injury due to the increased expression and 
requirement of α7β1 integrin in this muscle. 
Since our data indicates that soleus muscles of LARGEmyd/myd mice are 
protected from contraction-induced injury and that this is correlated with 
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increased α7β1 integrin expression in soleus muscle, we would predict that 
increased expression of α7β1 integrin in fast muscles might also provide 
protection against contraction-induced injury.  While this hypothesis remains to 
be formally tested in LARGEmyd/myd mice, previous studies have shown that 
transgenic overexpression of integrins in dystrophin-deficient mouse models can 
partially alleviate the dystrophic pathology.  Expression of rat α7 integrin in 
mdx:utr -/- animals resulted in an improvement in muscle integrity, a decrease in 
mononuclear cell infiltrate, and correlated with an increase in lifespan (50).  
Additionally, when α7 integrin was overexpressed in muscles of healthy animals, 
exercised-induced muscle injury was minimized as demonstrated by a reduction 
in Evans Blue Dye uptake post-exercise (98).  This suggests that an increase in 
α7 integrin expression can provide protection against sarcolemma damage in fast 
muscles.  Finally, the combined loss of dystrophin and α7 integrin causes an 
even more severe muscular dystrophy than the loss of either alone (96) which 
suggests that the DGC and α7β1 integrin have compensatory functions in 
skeletal muscle. 
 The striking differences in susceptibility to contraction-induced damage in 
LARGEmyd/myd soleus and EDL muscles, and the markedly higher expression of 
α7β1 integrin in soleus muscle compared to EDL and gastrocnemius muscles 
indicates that there are important fiber type specific differences in the interactions 
between the basal lamina and the cytoskeleton in muscle fibers.  Specifically, the 
functions of the DGC and α7β1 integrin complexes may be fiber type specific.  
PGC-1α is a transcriptional activator that has been shown to play a critical role in 
driving the slow muscle fiber gene program.  This protein is highly expressed in 
slow fibers and when transgenically overexpressed throughout skeletal muscle, 
results in a conversion to a slow-twitch fiber phenotype (185).  Interestingly, 
overexpression of PGC-1α in mdx mice partially improved the muscular 
dystrophy phenotype although the mechanism of action was not clearly identified 
(186).  However, mdx/PGC-1α mice were shown to have decreased levels of 
serum creatine kinase and decreased levels of Evans Blue Dye uptake following 
downhill running which supports the hypothesis that part of the effect may be 
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mediated by an increase in protection of the sarcolemma.  This suggests that 
although most of the downstream transcriptional events related to PGC-1α 
expression has focused on metabolic genes, the induction of a slow muscle gene 
program may also produce downstream changes that affect expression of ECM 
receptors, particularly that of α7β1 integrin resulting in its increased sarcolemmal 
expression and leading to protection from contraction-induced injury.  While the 
overexpression of PGC-1α likely results in a numbers of changes in gene 
transcription, the specific overexpression of α7β1integrin in skeletal muscle can 
increase muscle fiber viability without significantly affecting the transcription of 
other proteins and may be beneficial as a potential therapeutic for muscular 
dystrophy patients (187).  This also supports the conclusions that the alleviation 
of muscle damage and dystrophic phenotype observed when α7 integrin is 
transgenically expressed in animal models is due to the specific function of 
α7β1integrin at the sarcolemma and not due to altered expression of other 
proteins that may also contribute to enhanced viability of muscle fibers. 
 While the soleus muscle of LARGEmyd/myd mice contains a substantial 
number of fast-twitch muscle fibers, we did not observe a partial deficit in 
contraction-induced injury.  This suggests that interactions of slow muscle fibers 
with the extracellular matrix through β1containing integrins may also help 
stabilize neighboring fast muscle fibers from contraction-induced injury.  Previous 
studies have shown that striated muscle from animals with an impaired DGC 
typically have a higher degree of uptake of Evans Blue Dye in large patches of 
neighboring fibers rather than randomly distributed in single fibers throughout the 
muscle (52).  This supports the hypothesis that strong lateral interactions of 
muscle fibers with the extracellular matrix between neighboring fibers, through 
either dystroglycan or integrin, are critical for the protection of both individual 
fibers and the integrity of the entire muscle during normal muscle contractile 
activity.  Finally, it is important to remember that human skeletal muscle is 
composed of a mixture of fiber types and in many respects, the mouse soleus 
better models this typical composition of human skeletal muscle (188).  
Therefore, understanding the complete functions of dystroglycan in both fast-
47 
 
twitch and slow-twitch skeletal muscle and the relative functional contributions of 
dystroglycan and integrins in the different fiber types will have significant 
implications for future therapeutics aimed at treating muscular dystrophy.   
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Figure 2-1) Impaired dystroglycan glycosylation and muscle histology in 
LARGEmyd mice.  Altered dystroglycan glycosylation is not sufficient to cause 
muscular dystrophy in heterozygous LARGEmyd mice.  Immunoblots of whole 
muscle lysates (A) from quadriceps muscle of wild-type (W), heterozygous (H), or 
LARGEmyd/myd (M) mice were stained with antibodies against glycosylated α-
dystroglycan (IIH6) or β-dystroglycan (β -DG).  Altered glycosylation of mice 
heterozygous for the LARGEmyd mutation is demonstrated by a downward shift in 
the molecular weight of α-dystroglycan.  Hematoxylin and eosin staining (B) of 
mouse gastrocnemius, EDL and soleus muscles shows that while all three 
muscles of LARGEmyd/myd (myd) mice are dystrophic, heterozygous (het) muscles 
are indistinguishable from healthy wild-type littermates (WT).  LARGEmyd/myd 
soleus, EDL and gastrocnemius muscles contain fibers of heterogeneous size, 
several regenerating fibers indicated by internalized nuclei, and mononuclear cell 
infiltrate (indicated by black arrows).  All muscles were dissected from wild-type, 
heterozygous, and LARGEmyd/myd mice aged 30 weeks and frozen in liquid 
nitrogen cooled isopentane.  Scale bar represents 100 µm. 
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Figure 2-2) In vitro contractile function of LARGEmyd muscle EDL and 
soleus muscle.  LARGEmyd/myd soleus muscle is weak but not sensitive to 
contraction-induced injury.  Absolute (A) and specific (B) force was measured in 
vitro using soleus and EDL muscles isolated from 4-5 month-old wild-type (WT), 
heterozygous (het), or LARGEmyd/myd (myd) mice.  While absolute and specific 
force was significantly reduced in both LARGEmyd/myd soleus and EDL muscles, 
heterozygous mice showed no difference in either muscle when compared to 
wild-type animals.  Contraction-induced injury was performed by subjecting each 
muscle to two (C) or five (D) lengthening contractions of 30% strain.  In both 
soleus and EDL muscles from heterozygous mice, measured force deficits were 
not different from wild-type muscle.  Although force deficits measured in EDL 
muscles of LARGEmyd/myd mice were significantly higher than wild-type, no such 
difference was observed in the soleus muscle. 
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Figure 2-3) Laminin binding activity and immunofluorescent staining of 
LARGEmyd gastrocnemius and soleus muscle.  Loss of glycosylated 
dystroglycan occurs in both soleus and gastrocnemius muscle of LARGEmyd/myd 
mice and results in decreased laminin binding activity.  Gastrocnemius and 
soleus muscles were dissected from 36- week old wild-type and LARGEmyd/myd 
mice.  Frozen sections were stained separately for β-dystroglycan (bDG), 
glycosylated α-dystroglycan (IIH6), or laminin.  Sections were imaged at regions 
where the gastrocnemius (bottom right) and soleus (top left) muscles lie adjacent 
to one another, and the boundary of each is indicated by the dashed line (A).  
Loss of dystroglycan glycosylation in both muscles is indicated by a loss of 
reactivity with the IIH6 antibody.  Despite loss of dystroglycan glycosylation, the 
presence of laminin, an important dystroglycan ligand in skeletal muscle, is 
retained.  Scale bar represents 200 µm.  Loss of dystroglycan glycosylation 
results in loss of laminin binding activity in both soleus and EDL muscles (B).  
WGA-purified fractions of pooled muscle tissue from wild-type (WT) and 
LARGEmyd/myd (myd) mice were isolated, quantified, and coated onto 96-well 
plates.  Laminin binding activity was determined by overlaying wells with a range 
of concentrations of laminin between 0.2 - 20 nM. 
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Figure 2-4) β1 integrin expression 
in fast-twitch versus slow-twitch 
muscle.  β1 integrin is highly 
expressed at the sarcolemma of 
muscle containing a large 
percentage of slow fibers.  
Immunoblots were stained with IIH6 
and anti-β-dystroglycan.  In both rat 
(A) and mouse (B), α-dystroglycan 
from soleus muscle appears to run at 
a higher molecular weight than α-
dystroglycan from EDL muscle.   
Immunoblots were also stained for 
β1 integrin (β1 Itgn) and dysferlin 
(Dysf).  In both rat and mouse, β1 
integrin appears to be more highly 
expressed in soleus muscle.  No 
differences were observed in the 
expression of dysferlin, a protein 
thought to be involved in membrane 
repair.  Immunofluorescent staining 
of soleus (S)/ gastrocnemius (G) 
muscle sections shows that the 
increased expression of β1 integrin 
observed in the soleus muscle is due 
to increased expression at the 
sarcolemma (C).  Co-staining with an 
antibody specific to slow myosin 
demonstrates that increased 
expression of β1 integrin in the 
soleus muscle corresponds to 
muscle that contains a high 
proportion of slow fibers.  The 
decreased expression of β1 integrin 
in predominantly fast fibers is also 
demonstrated by reduced staining in 
the EDL muscle (D, lower panel) 
when compared to the soleus (D, 
upper panel) when both sections 
were imaged at the same exposure. 
Scale bar represents 200 µm.   
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Figure 2-5) α7 integrin expression 
in fast-twitch versus slow-twitch 
muscle. Skeletal muscle contains 
multiple α integrin isoforms capable 
of forming dimers with β1 integrin.  
Microsome or WGA-purified fractions 
were isolated from either soleus and 
EDL muscle from Sprague-Dawley 
rats or whole muscle from neonatal 
mice.  Staining with an antibody to 
α7 integrin resulted in the detection 
of multiple bands, two of which have 
molecular weights corresponding to 
a non-glycosylated (100 kDa) and 
glycosylated (120 kDa) form of α7 
integrin (A, B).  While no difference 
in expression of α7 integrin was 
detected in the 100 kDa band, the 
120 kDa band appeared to be more 
highly expressed in soleus (S) 
muscle than in EDL (E) muscle.  
Additionally, α5 integrin was 
expressed at equally low levels in 
both muscles when compared to 
neonatal muscle (A, B).  In a pattern 
similar to β1 integrin, 
immunofluorescent staining of 
mouse soleus (S)/ gastrocnemius 
(G) muscle sections showed that α7 
integrin is more highly expressed at 
the sarcolemma of soleus muscle 
(C).  Scale bar represents 200 µm.   
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Figure 2-6) Interstitial fibrosis in LARGEmyd skeletal muscles.   
Sirius Red staining of mouse gastrocnemius (Gstrc), EDL, and soleus (Sol) 
muscles shows that all three muscles of LARGEmyd/myd (myd) mice demonstrate 
an increase in interstitial fibrillar collagen deposition (red staining) while 
heterozygous (het) muscles are indistinguishable from that of healthy wild-type 
littermates (WT).  Additionally, fibers of heterogenous size are apparent in 
LARGEmyd/myd muscle.  All muscles were dissected from 30-week old wild-type, 
heterozygous and LARGEmyd/myd mice and frozen in liquid nitrogen cooled 
isopentane.  Scale bar represents 100 µm. 
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CHAPTER 3 
 
Hyperglycosylation by LARGE protects mouse skeletal muscle from 
contraction induced-injury 
 
ABSTRACT 
Dystroglycan is a glycosylation-dependent extracellular matrix receptor essential 
for maintaining lateral connections between the sarcolemma and basal lamina in 
skeletal muscle.  Several glycosyltransferases have been identified in which 
mutations result in muscle disease and are associated with a reduction in 
dystroglycan glycosylation in skeletal muscle.  We have previously demonstrated 
that in an animal model of glycosylation-deficient muscle dystrophy, loss of 
glycosylation and ligand binding activity of dystroglycan renders muscle 
susceptible to contraction-induced damage.  To further determine the importance 
of dystroglycan glycosylation in skeletal muscle function, transgenic mice were 
generated that direct overexpression of Like-acetylglucosaminyltransferase 
(LARGE) in differentiated muscle fibers.  We tested the hypothesis that 
overexpression of LARGE would result in enhanced dystroglycan glycosylation 
and function above that observed in normal muscle.  Skeletal muscle of MCK-
LARGE transgenic mice demonstrated hyperglycosylation of dystroglycan that 
coincided with a significantly elevated laminin binding affinity compared to that of 
wild-type muscles.  Additionally, fast-twitch skeletal muscle from transgenic mice 
demonstrated enhanced protection from contraction-induced injury such that 
force deficits following injury were significantly reduced as compared to muscle of 
wild-type littermates. This suggests that hyperglycosylation and enhanced 
function of dystroglycan via increased activity of the enzyme LARGE may be 
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therapeutic not only in inherited glycosylation-deficient muscular dystrophy but 
also in acquired diseases or disability resulting from muscle injury. 
INTRODUCTION 
Dystroglycan is an extracellular matrix receptor and central component of 
the dystrophin-glycoprotein complex (DGC), a protein complex essential for 
skeletal muscle function, yet one that is disrupted in several forms of muscular 
dystrophy.  Dystroglycan is transcribed from the DAG1 gene and post-
translational cleavage produces two subunits that remain tightly associated at the 
plasma membrane (159).  β-dystroglycan contains a single transmembrane 
domain and interacts intracellularly with dystrophin and extracellularly with α-
dystroglycan.  Anchored to the extracellular face of the sarcolemma by β-
dystroglycan, α-dystroglycan can interact with a number of extracellular ligands, 
including agrin (137), neurexin (189), perlecan (190), and laminin (12, 191).  
Through high affinity binding of α-dystroglycan to laminin and β-dystroglycan to 
dystrophin, dystroglycan acts as a bridge between the basal lamina and the 
cellular cytoskeleton and mutations that disrupt this link can result in muscular 
dystrophy (12).  Dystrophin mutations account for one of the most common forms 
of muscular dystrophy, Duchenne muscular dystrophy (DMD)  with the loss of 
dystrophin function in a mouse model of DMD rendering muscle highly 
susceptible to contraction-induced muscle damage (38, 39).  This has led to the 
hypothesis that one of the primary functions of dystroglycan and the DGC is to 
stabilize the sarcolemma during successive muscle contractions (12). 
In order to bind laminin and other extracellular ligands, α-dystroglycan 
requires extensive O-linked glycosylation (160), the reduction or complete 
absence of which is the basis for a group of diseases referred to as the 
“dystroglycanopathies”.  These diseases are characterized by progressive 
muscle dysfunction and often include additional clinical symptoms such as 
developmental delay, cobblestone lissencephaly and occular abnormalities.  In 
many of these diseases, the mutation responsible has been identified in one of 
several glycosyltransferase genes which are required for the extensive O-linked 
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glycosylation of dystroglycan within its central mucin domain.  Mutations resulting 
in the development of Walker-Warburg syndrome, one of the most severe of the 
dystroglycanopathies, have been identified in the enzymes protein-O-
mannosyltransferase 1 (POMT1) and POMT2 (150, 151).  These enzymes have 
been shown to catalyze the first step, an addition of mannose, in the synthesis of 
a tetrasaccharide, NeuAcα2-3Galβ1-4GlcNAcβ1-2Man-S/T, identified on α-
dystroglycan (171).  The second step, an addition of a N-acetylglucosamine 
(GlcNAc) residue to mannose is catalyzed by protein-O-mannose β1,2-N-
acetylglucosaminyltranferase (POMGnT), the enzyme mutated in muscle-eye 
brain-disease (142).  In addition to the tetrasaccharide that is synthesized in part 
by the enzymes POMT1, POMT2, and POMGnT, the mucin domain of α-
dystroglycan has been shown to contain several additional glycans (171-173, 
192, 193); however, the enzymes required for their synthesis are still unknown.  
Additional mutations have been identified in fukutin that cause Fukuyama 
congenital muscular dystrophy, fukutin-related peptide (FKRP) that can result in 
either limb-girdle muscular dystrophy 2I (147) or congenital muscular dystrophy 
1C (148) and like-acetylglucosaminyltransferse (LARGE) that can cause both 
congenital muscular dystrophy 1D (194) and Walker-Warburg syndrome (195).  
However, the catalytic activity and the precise nature of the reaction catalyzed by 
fukutin, FKRP, and LARGE is unclear.  Additionally, in many forms of 
dystroglycanopathy, the causative gene remains unidentified (196). 
LARGE is a putative glycosyltransferase that contains two potential 
catalytic DXD motifs and has homology to both 1,3-N-
acetylglucosaminyltransferase and bacterial glycosyltransferase (167).  In order 
for LARGE-mediated glycosylation of dystroglycan to occur, LARGE must be 
able to directly bind to the N-terminus of α-dystroglycan (169), and it appears that 
this is essential  for modifying laminin-binding glycans on specific threonines 
within the mucin domain nearest the N-terminus (197).  Additionally, α- 
dystroglycan was recently shown to contain a transient phosphorylated mannose 
residue that was present in muscle containing a mutation in LARGE, suggesting 
that LARGE may modify phosphorylated mannose structures in order to form 
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laminin binding glycans (174).  Viral-mediated overexpression of LARGE in 
myoblasts cultured from dystroglycanopathy patients was capable of restoring 
dystroglycan glycosylation and laminin binding, despite that the cells harbored 
mutations in enzymes other than LARGE (170).  This suggests that LARGE may 
be able to circumvent defects in the stalled synthesis of glycans due to mutations 
in either POMT1 or POMGnT and moreover, may be able to add novel laminin-
binding glycans to dystroglycan.   
The LARGEmyd mouse model of glycosylation-deficient muscle dystrophy 
demonstrates hypoglycosylation of α-dystroglycan (167), and we and others have 
shown that loss of LARGE-mediated glycosylation of α-dystroglycan renders 
muscle susceptible to contraction-induced injury (22, 48).  Specific interactions 
between dystroglycan and laminin within the extracellular matrix are critical for 
tightly anchoring the basal lamina to the sarcolemma (22) and therefore, LARGE-
mediated glycosylation of dystroglycan appears to be essential for conferring the 
laminin binding activity of dystroglycan necessary for maintaining tight 
association with the basal lamina.  Consequently, the reduction in these 
interactions due to mutations in glycosyltransferases known to modify 
dystroglycan leaves the sarcolemma vulnerable to mechanical injury.  Therefore, 
we hypothesized that enhanced interactions between dystroglycan and laminin 
would further protect the sarcolemma from contraction-induced injury.  Here, we 
demonstrate that overexpression of a muscle-specific LARGE transgene causes 
dramatic hyperglycosylation of dystroglycan, significantly increases laminin 
binding activity, and protects muscle from lengthening-contraction induced 
mechanical injury .   
METHODS 
Generation of Transgenic Mice. A construct containing the human LARGE 
cDNA, a C-terminal myc sequence and a BGH polyadenylation signal was 
amplified via PCR from LARGEmyc-pCDNA3 and cloned into the pCR 2.1 TOPO 
vector.  An MCK promoter/enhancer sequence (received from Jeffrey 
Chamberlain, Department of Neurology, University of Washington School of 
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Medicine, Seattle, WA) was amplified and digested with NdeI and XhoI to 
generate two pieces that were ligated in a two step ligation protocol 5’ to the 
LARGEmyc coding sequence.  The resulting construct containing the transgene 
was linearized via NotI digestion and the University of Michigan Transgenic 
Animal Model Core was utilized to perform injections into C57Bl/6 mouse eggs.  
The generated pups were screened and two founders were identified by PCR of 
genomic DNA from tail biopsies using two sets of transgene specific primers.  All 
animals were housed in a specific pathogen free (SPF) barrier facility in the Unit 
for Animal Medicine at the University of Michigan and all experiments were 
approved by the University of Michigan Committee for the Use and Care of 
Animals (UCUCA).  Transgenic and wild-type littermates used in all experiments 
described were 31-32 weeks of age. 
Western Blots.  Muscle tissue used for western blot analysis was collected from 
deeply anesthetized animals and immediately frozen in dry ice prior to 
processing.  Microsome fractions were created by homogenizing samples in ice-
cold homogenization buffer (20 mM sodium pyrophosphate, 20 mM sodium 
phosphate (monobasic), 1 mM magnesium chloride, 5 mM EDTA, and 0.303 M 
sucrose, pH 7.1).  Homogenate was subjected to a low-speed (10,000 g) 
centrifugation to remove cellular debris and a high-speed (45,000 g) spin in order 
to isolate the membrane fraction.  Resulting pellets were resuspended in Buffer I 
(0.303 mM sucrose, 20 mM Tris-maleate, pH 7.0) and quantified using the Bio-
Rad Bradford assay.  Additional tissues were homogenized in a Triton-X 100 
lysate buffer and subjected to a low-speed spin (10,000 g) to clear cellular debris.  
Lysates were quantified using the Bio-Rad DC assay.  All buffers contained 
protease inhibitors (0.0 µg/ml pepstatin A, 2 kallikrein inhibitor units/ ml aprotinin, 
1 µg/ml leupeptin, 0.4 mM PMSF, 0.6 mN benzamidine).  Samples were 
separated on a 3-15% polyacrylamide gel and transferred to polyvinylidene 
fluoride membrane (Millipore).  Membranes were initially reversibly stained with 
PonceauS in order to verify equal loading and incubated in a blocking solution 
containing in 5% nonfat dry milk in TBS-T (120-150 mM sodium chloride, 50 mM 
Tris, 0.05% Tween-20).  All blots were blocked for 1-2 hours and incubated in 
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primary antibody for 2 hours to overnight.  Primary antibodies included IIH6 (gift 
from Dr. Kevin Campbell, University of Iowa, Iowa City, IA) and the anti-myc 
9E10 antibody (Sigma). After three 5-10 minute washes, membrane were 
incubated in secondary antibodies conjugated to horseradish peroxidase (HRP) 
for 1-2 hours. Following three 5-10 minutes washes, membrane were incubated 
in chemiluminescent substrate (Thermo scientific) and digitally developed using 
an Alpha Innotech Fluorchem. 
Immunofluorescence and Histology. Muscles were carefully dissected from 
deeply anesthetized animals and immediately frozen in liquid nitrogen-cooled 
isopentate.  Frozen samples were cut into 8-10 uM cross or longitudinal sections 
with a cryostat and stored at -80° until further processed for hematoxylin and 
eosin or immunofluorescent staining.  For immunofluorescent staining, slides 
were rehydrated in PBS and incubated in a blocking buffer containing 5% bovine 
serum albumin and 0.05% Triton-X 100 in PBS.  Slides were incubated in 
primary antibody for 2-3 hours and secondary antibody for 1-1.5 hours with three 
5 min washes in between incubations.  Primary antibodies included an anti-myc 
A-14 polyclonal (Santa Cruz), IIH6 (gift from Dr. Kevin Campbell, University of 
Iowa, Iowa City, IA), and anti-laminin L-9393 (Sigma).  Slides were mounted in 
Permafluor (Thermo Scientific) and imaged on an Olympus BX-51fluorescence 
microscope. 
Solid-phase Laminin Binding Assay.  Laminin binding assays were performed 
as described previously (my paper). Wheat germ agglutinin (WGA)-purified 
muscle fractions were coated onto 96-well microplate and incubated with 
increasing concentrations of laminin (0.02 – 2nM) from Invitrogen.  Laminin 
binding was detected using the primary L-9393 (Sigma) antibody and a 
secondary antibody conjugated to horseradish peroxidase (HRP).  Antibody 
binding was detected using o-phenylenediamine (OPD)-citrate phosphate buffer 
(CPB) and stopped with 2M H2SO4. 
In Vitro Muscle Function and Injury Protocol. Contractile measurements were 
performed as previously described (177). EDL and soleus muscle were carefully 
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dissected from anesthetized mice and tied to a servomotor (Aurora  Scientific, 
model 300) and a force transducer (Kulite Semiconductor) using 5.0 silk suture.  
Muscle were maintained in 25°C bath containing Krebs mammalian Ringer 
solution bubbled continuously with 95% O2 and 5% CO2 to stabilize pH at 7.4.  
Each muscle was stimulated by square wave pulses delivered between two 
platinum electrodes connected to a high-power biphasic current stimulator 
(Aurora Scientific, model 701B).  Electrical pulse properties and servomotor 
activity was controlled and force transducer recorded from an IBM-compatible 
personal computer with custom-designed software (LabVIEW 7.1, National 
Instruments, Austin, TX).  Upon determination of Lo (optimal muscle length) and 
optimal voltage and frequency, muscle were held at Lo and subjected to trains of 
pulses (300 ms for EDL, 900 ms for soleus) to generate maximum isometric 
contraction (Po).  Mean cross-sectional area (CSA) was calculated by dividing the 
muscle wet mass by the product of fiber length (Lf) and the density of mammalian 
muscle (1.06 g/cm3) and specific force (sPo) was determined by dividing Po by 
CSA.  The muscle injury protocol was performed as described previously (48).  
Following contractile measurements, muscle were stimulated to achieve 
maximum twitch force (Po) and immediately stretched through a strain of 30% 
relative to Lf at a velocity of 1 Lf/s. Total stimulation time was 400ms for EDL 
muscle, 600 ms for soleus muscle.  After stimulation, muscles were returned to 
Lo and subjected to 4 additional 30% stretches, each with 12 seconds in between 
for a total of five stretches per muscles.  Force deficit was calculated as the 
decrease in Po observed after each stretch as a percentage of the Po 
immediately prior to the lengthening contraction. 
Statistics. For contractile function experiments, unpaired t-tests were used to 
compare differences in results obtained between wild-type and MCK-LARGE 
littermates.  Statistical significance was established for P-value less than 0.05.  
Error bars represent SEM. 
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RESULTS 
MCK-LARGE transgenic animals demonstrate hyperglycosylation of α-
dystroglycan and increased laminin binding activity.  Transgenic mice that 
express full length LARGE exclusively in striated muscle were generated using a 
muscle creatine kinase (MCK) promoter/enhancer sequence to drive expression 
of the human LARGE cDNA sequence (Fig. 3.1A).  The transgene contained a c-
terminal myc epitope used to detect LARGE protein expression.  Two founders 
were generated that demonstrated expression of the LARGE-myc in cardiac and 
skeletal muscle.  Western blot analysis was performed on Triton-X lysates from 
heart and quadriceps muscle of MCK-LARGE and wild-type littermates to 
determine whether human LARGE was capable of glycosylating α-dystroglycan 
as determined by increased reactivity with the glycosylation specific IIH6 
antibody.  Although α-dystroglycan has a predicted molecular weight of ~74 kDa 
based on the amino acid sequence, it has been observed to run as a broad 
smear on SDS-PAGE with a molecular weight of 120-156 kDa as a result of 
extensive glycosylation.  The molecular weight of α-dystroglycan from both lines 
of transgenic animals was dramatically increased, suggesting that LARGE is 
capable of either extending or adding additional glycans to α-dystroglycan (Fig. 
3.1B).  No difference in expression of β-dystroglycan between wild-type and 
transgenic muscle was observed (not shown).  Western blots of muscle 
microsome preparations from wild-type and MCK-LARGE skeletal muscle 
confirmed expression of LARGE-myc as detected by the anti-myc 9E10 antibody 
(Fig. 3.1C).  Since glycosylation of α-dystroglycan is essential for enabling 
dystroglycan to function as an extracellular matrix receptor, we sought to 
determine how hyperglycosylation of α-dystroglycan affected laminin binding 
affinity.  Laminin binding assays performed on wheat germ agglutinin (WGA)-
purified fractions of gastrocnemius muscle isolated from two transgenic and two 
wild-type animals demonstrated that transgene expression resulted in a nearly 5-
fold increase in laminin binding activity of the muscle (Fig. 3.1D).  These data 
demonstrate that LARGE overexpression in skeletal muscle results in the 
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addition of laminin binding glycans on α-dystroglycan and significantly enhances 
the overall laminin binding activity of the skeletal muscle. 
Representative muscle sections from wild-type and MCK-LARGE mice 
also demonstrate the expression and localization of transgenic LARGE-myc.  
Native LARGE is localized to the golgi apparatus (198) and detection of myc in 
muscle using the polyclonal A-14 antibody identified transgenic LARGE in all 
fibers in a pattern consistent with golgi localization (Fig. 3.2B).  The creatine 
kinase gene has been shown to be differentially expressed in fast-twitch and 
slow-twitch fibers (199).  Therefore, to verify that all MCK-LARGE muscles 
expressed the transgene and demonstrated hyperglycosylation of dystroglycan, 
several muscle groups were analyzed.  IIH6 stained cross sections of extensor 
digitorum longus (EDL) (Fig. 3.2D) and soleus muscle (Fig. 3.2F) of MCK-
LARGE mice showed increased reactivity beyond that observed in wild-type 
muscle (Fig. 3.2C, EDL; Fig. 3.2E, soleus) indicating that hyperglycosylation of α-
dystroglycan in transgenic animals was not restricted to either fast-twitch or slow-
twitch muscle.  Additionally, hematoxylin and eosin stained muscle sections from 
wild-type (Fig. 3.2G) and transgenic (Fig. 3.2H) animals revealed that increased 
LARGE expression and consequent hyperglycosylation of α-dystroglycan does 
not affect normal muscle morphology since sections from MCK-LARGE mice 
were indistinguishable from wild-type sections.  Laminin staining in skeletal 
muscle sections from both wild-type and transgenic animals did not appear to be 
altered between the two tissues (Fig. 3.2I, wild-type: 3.2J, MCK-LARGE), 
suggesting that the enhanced laminin binding activity of transgenic muscle does 
not result in changes in laminin retention in the extracellular matrix.   
Contractile function in MCK-LARGE muscle is comparable to wild-type 
muscle.  In order to demonstrate that LARGE overexpression in skeletal muscle 
is not deleterious to skeletal muscle function, in vitro contractile measurements 
were performed on EDL and soleus muscles from wild-type and MCK-LARGE 
animals.  Neither the EDL nor the soleus muscle from MCK-LARGE mice was 
different in mass (EDL: 10.72 mg ± 0.58, soleus: 9.98 mg ± 0.47) from the 
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corresponding muscle in wild-type animals (EDL: 10.33 ± 0.54, soleus: 8.95 mg ± 
0.34) indicating that LARGE overexpression did not result in significant changes 
to muscle mass (Fig. 3.3A).  Additionally, absolute forces measured in EDL (WT: 
439 mN +/- 19, TG: 405 mN +/- 13) and soleus muscle (WT: 231 mN ± 6, TG: 
229 mN ± 7.4) did not reveal any significant differences between transgenic and 
wild-type muscle (Fig. 3.3B).  However, specific force calculations resulted in 
significant differences between transgenic and wild-type mice in both EDL and 
soleus muscle (Fig. 3.3C).  No differences in body weight were observed 
between the different genotypes which suggests that muscle from MCK-LARGE 
does not undergo significant hypertrophy (Fig. 3.3D).  
Muscles of MCK-LARGE mice display increased protection from 
contraction-induced injury.  Previously we reported that mice containing a 
mutation in the LARGE gene demonstrate reduced glycosylation of α-
dystroglycan concomitant with a susceptibility to lengthening contraction-induced 
damage in muscles composed of predominantly fast-twitch fibers (48).  
Susceptibility to contraction-induced injury is a common feature of muscular 
dystrophies associated with mutations in the dystrophin-glycoprotein complex 
and interactions between laminin and α-dystroglycan are particularly critical for 
providing stability during mechanical injury by anchoring the basal lamina to the 
sarcolemma (22).  Therefore, we hypothesized that enhanced α-dystroglycan 
glycosylation and increased laminin binding affinity would provide additional 
stability to the sarcolemma and as a result, MCK-LARGE muscle would be more 
resistant to lengthening contraction-induced injury than wild-type muscle.  
Lengthening contractions of 30% strain were performed in vitro on both EDL and 
soleus muscles from MCK-LARGE and wild-type littermates.  Injury was 
determined by calculating the difference in maximal force production prior to and 
after each contraction and the force deficit was expressed as a percentage of the 
maximal force production.  With each successive contraction, an increase in the 
force deficit was observed in both wild-type and transgenic muscle.  The mean 
force deficits measured in the MCK-LARGE EDL muscle after the first and 
second lengthening contraction (LC1: 7.08% +/- 0.42, LC2: 14.29% +/- 0.39) 
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were respectively 22.5% and 17.3% less than the mean force deficits measured 
in wild-type EDL muscle (LC1: 9.14% +/- 0.45, LC2:17.27% +/- 0.94) which 
indicated significant differences in susceptibility to contraction-induced injury 
between the two muscles (Fig. 3.4).  Furthermore, although the data was not 
statistically significant, force deficits trended lower in MCK-LARGE EDL after the 
additional 3rd, 4th and 5th lengthening contraction (contraction 3-5 not shown).   
In contrast to the results obtained in the EDL muscle, significant differences were 
not observed between force deficits measured in wild-type and transgenic soleus 
muscle (Fig. 3.4).  
DISCUSSION 
Lengthening contractions are particularly injurious to skeletal muscle and 
can disrupt force generating/ transmitting structures and damage the 
sarcolemma.  The dystrophin-glycoprotein complex (DGC) is essential for binding 
proteins within the basal lamina that surrounds each muscle fiber and is thought 
to provide structural support to the sarcolemma during cycles of contraction and 
relaxation.  Consequently, several forms of muscular dystrophy are thought to 
result in part from compromised sarcolemma integrity due to impaired function or 
loss of components in the DGC.   Recently, it has also been shown that the DGC 
can function to transmit forces laterally through costameres to the epimysium and 
by doing so, may also serve to protect muscle fibers from contraction-induced 
injury (128).  Here, we demonstrate that enhancing connections with the basal 
lamina via increased affinity for extracellular laminin can result in significant 
protection of the muscle from lengthening-contraction induced injury. 
In the present study, we observed a protection from mechanical injury only 
in muscle of predominantly fast-twitch fibers despite having found that both fast-
twitch and slow-twitch muscle were hyperglycosylated as a result of transgene 
expression.  This was particularly apparent after the first and second lengthening 
contraction and force deficits measured in transgenic muscle trended lower than 
those in wild-type muscle after three additional contractions.  We also 
demonstrated that α-dystroglycan, as detected by the glycosylation specific IIH6 
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antibody, ran at a higher molecular weight than α-dystroglycan from wild-type 
muscle.  This suggests that human LARGE is capable of either extending 
glycans already present or adding additional novel glycans on the ~50 serine and 
threonine residues located within the mucin domain of α-dystroglycan.  In either 
case, this results in a nearly 5-fold increase in laminin binding affinity in 
transgenic muscle.  Since high-affinity laminin binding activity is reduced in 
dystroglycan gene-targeted mice (101), it is likely that this increase in laminin 
binding activity can be attributed to enhanced dystroglycan glycosylation in MCK-
LARGE mice.  This results in a strengthening of the connections between the 
basal lamina and the sarcolemma and underlies the effects we observe after 
subjecting the muscle to a series of lengthening contractions – namely, that 
enhanced laminin binding coincides with a greater degree of protection from 
contraction-induced injury.  In support of this, muscle lacking functional glycans 
on α-dystroglycan, as a result of LARGE mutation, are highly susceptible to 
contraction-induced injury (48) and exhibit defects in the basal lamina (22).   
 A recent similar study postulated that hyperglycosylation of dystroglycan 
via a LARGE transgene does not provide protection from contraction-induced 
injury and demonstrated that muscle containing hyperglycosylated dystroglycan 
was more susceptible to mechanical injury (200).  This study utilized the tibialis 
anterior muscle, also a predominantly fast-twitch muscle, and performed 
lengthening-contractions in situ.  Although the specific muscle utilized and the 
protocol was different from our study, the animals were 8 months of age, 
approximately the same age and genetic background as those used in our study.  
An explanation that accounts for the increased susceptibility of LARGE 
transgenic muscle to mechanical injury by the authors of this study was the 
possibility that the hyperglycosylation of α-dystroglycan may negatively affect 
turnover of the basal lamina.  Since we observed an opposite result despite 
hyperglycosylation of α-dystroglycan, the most probable explanation that 
accounts for the differences we observed in our study is related to the method of 
transgene expression.  While the Brockington study employed a ubiquitous 
promoter to drive expression of LARGE in all tissues, we used the muscle 
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creatine kinase (MCK) promoter to direct LARGE expression exclusively in 
differentiated muscle fibers.  This promoter/enhancer construct has also been 
used to drive muscle-specific expression of dystrophin in mdx muscle, and the 
dystrophin transgene was not detected in uterine smooth muscle, liver, or brain 
(201).  Additionally, the muscle creatine kinase gene is not expressed until later 
in development once proliferating myoblasts exit the cell cycle and commit to a 
muscle cell lineage (202).  Therefore, it is possible that dystroglycan has 
additional functions during muscle development, and that early 
hyperglycosylation of dystroglycan by ubiquitous overexpression of LARGE may 
negatively impact skeletal muscle function.   
While the EDL muscle from transgenic animals demonstrated a protection 
from contraction-induced injury greater than that observed in wild-type muscle, 
we did not observe any difference between the two genotypes in soleus muscle.  
In some respects, this was expected since we previously demonstrated that in 
LARGE-deficient animals, only the EDL muscle was highly susceptible to 
lengthening contraction-induced injury (48).  Force deficits measured in 
LARGEmyd soleus were not different from those measured in wild-type animals 
despite a lack of dystroglycan glycosylation in this muscle.  As a partial 
explanation for this, we showed that soleus muscle contained a much higher 
expression of an alternative laminin receptor, α7β1 integrin, as compared to 
muscle composed primarily of fast-twitch fibers.  Therefore, it appears that slow-
twitch muscle may utilize different or additional laminin receptors as a means to 
forge connections with the sarcolemma.  This would imply that in our transgenic 
mice, hyperglycosylated dystroglycan accounts for a greater percentage of 
laminin bound receptors in the EDL than it does in the soleus and could explain 
the observed diminished effect in the soleus.  While we did not see a protection 
in the soleus muscle, we cannot rule out the possibility that small increases were 
too low to be detected in our study.  
 Although symptoms observed in glycosyltransferase-deficient muscular 
dystrophy are thought to result from reduced dystroglycan glycosylation and 
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consequent impaired function, recent data suggests that the enzymes identified 
in these diseases may have multiple substrates in addition to dystroglycan (153, 
154, 203).  Zhang et al. showed that overexpression of LARGE in a clonal 
population of neural stem cells lacking the dystroglycan gene, still demonstrated 
an increase in IIH6 reactivity (153).  Additionally, in cells that were null for both 
dystroglycan and POMT2, LARGE overexpression resulted in the formation of a 
IIH6 binding epitope that could be removed when incubated with PNGase F 
which removes N-linked glycans.  This suggests that LARGE is capable of 
modifying both O-linked and N-linked glycans on additional substrates (154).  In 
light of these studies, we cannot definitively confirm that the effects we observed 
are specific to the enhanced glycosylation of α-dystroglycan.   However, as these 
studies were performed using neuronal cell populations, it is still unclear whether 
or not additional substrates for LARGE exist in skeletal muscle.  When LARGE 
was overexpressed using the ubiquitous CMV promoter (200), no additional IIH6 
reacting bands were present in transgenic brain, intestine, liver or kidney despite 
the detection of transgenic LARGE protein in these tissues.  This suggests that if 
there are additional LARGE substrates in these tissues, either a significant 
elevation in LARGE expression, beyond that expressed by the transgene, is 
required to generate IIH6 reactive glycans or that IIH6 reactive glycans are 
present in amounts too low to be detected using immunoblot methods. 
 We have demonstrated that hyperglycosylation of LARGE in otherwise 
normal muscle does not result in deleterious effects to skeletal muscle function or 
overall animal health.  Although we do not observe any differences in maximal 
force production or in muscle mass, we see a slight decrease in calculated 
specific force of muscle from transgenic mice.  This appears to result from 
slightly elevated muscle mass in transgenic animals that did not result in a 
greater increase in total force production.  While the predominant function of 
dystroglycan is hypothesized to be related to its important function in basal 
lamina formation and stabilization of the sarcolemma during muscle contractions, 
several reports have highlighted a potential role in survival signaling downstream 
of laminin binding.   Inhibition of the binding between laminin and dystroglycan 
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results in a decrease in PI3K/AKT signaling, an important pathway mediating cell 
growth (112).  Since we observe a significant increase in laminin binding affinity 
which is most likely due to enhanced glycosylation of dystroglycan, this has the 
potential for enhancing PI3K/AKT signaling or additional pathways that may be 
downstream of dystroglycan and could result in muscle hypertrophy.  However, 
we do not observe any differences in body weight nor difference in ratio of wet 
mass to dry mass (data not shown), which suggests that muscle from MCK-
LARGE muscle is not undergoing significant hypertrophy or edema as a result of 
dystroglycan hyperglycosylation.  This suggests that hyperglycosylation of 
dystroglycan might have a slight negative effect on force production that is not 
accounted for by any structural changes within the muscles examined. 
Our results demonstrate that overexpression of human LARGE in both 
fast-twitch and slow-twitch mouse muscle results in hyperglycosylation of 
dystroglycan and significantly enhances the laminin binding activity of the 
muscle.  Additionally, this increase in laminin binding affinity of the muscle can 
significantly protect muscle from injury caused by lengthening contractions.  
Previously, it was demonstrated that in cell lines derived from patients with 
mutations in distinct glycosyltransferases involved in dystroglycan glycosylation,  
overexpression of LARGE was sufficient to bypass the genetic defect and restore 
functional glycosylation and laminin binding affinity of α-dystroglycan (170).  
Here, we demonstrate that this hyperglycosylation of dystroglycan by LARGE 
may also be beneficial in muscle diseases unrelated to the dystroglycanopathies 
by enhancing lateral connections in the muscle and providing protection from 
contraction-induced injury. 
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Figure 3-1) Muscle-specific expression of LARGE results in 
hyperglycosylation of α-dystroglycan and enhances laminin binding 
affinity.  The transgene was generated by fusing a myc-tagged human LARGE 
cDNA sequence upstream of a bovine growth hormone (BGH) polyadenylation 
signal and downstream of a muscle creatine kinase (MCK) promoter/enhancer 
sequence (A).  An immunoblot of Triton-X lysates (200 µg per lane) from heart 
and quadriceps muscle (skm) of wild-type (nTG) and two different lines of 
transgenic animals (TG1, TG2) was stained with the glycosylation-specific IIH6 
antibody to α-dystroglycan.  In both heart and skeletal muscle, expression of the 
transgene results in a dramatic increase in the molecular weight of α-
dystroglycan as evidenced by an upward shift of glycosylated dystroglycan in 
both transgenic lines (B).  Because of the high reactivity of the IIH6 antibody with 
transgenic dystroglycan, the blot was imaged at a low exposure and 
consequently, α-dystroglycan in wild-type skeletal muscle is barely visible.  
Microsomes from wild-type and transgenic (line 1) skeletal muscle (50 µg per 
lane) were stained with the 9E10 antibody that recognizes transgenic myc-
tagged LARGE (C).  Wheat germ agglutinin (WGA)-purified fractions of 
gastrocnemius muscle taken from two transgenic and two wild-type animals were 
coated onto 96-well plates, overlaid with increasing concentrations of laminin, 
and detected using the L-9393 anti-laminin antibody.  Compared to wild-type 
muscle, hyperglycosylated transgenic muscle demonstrated a nearly 5-fold 
increase in laminin binding activity (D).   
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Figure 3-2) Hyperglycosylation of 
α-dystroglycan is not restricted by 
fiber type and does not cause 
muscle pathology.  Frozen sections 
of wild-type and MCK-LARGE 
quadriceps muscle stained with the 
anti-myc A-14 antibody demonstrate 
ubiquitous expression of LARGE 
only in transgenic fibers (B) in a 
pattern consistent with localization in 
the golgi apparatus.  Reactivity is not 
detected in wild-type sections (A).  
Cross sections of either EDL (C,D) 
or soleus muscle (E, F) from wild-
type (C,E) and transgenic (D,F) 
animals stained with IIH6 
demonstrate that expression of the 
transgene results in a ubiquitous 
hyperglycosylation  of α-dystroglycan 
in both fast-twitch and slow-twitch 
muscle.  Hematoxylin and eosin 
stained sections of EDL muscle from 
wild-type (G) and transgenic (H) 
animals also show that muscle of 
transgenic animals is 
indistinguishable from wild-type 
muscle and does not display 
pathology as a result of transgene 
expression.  Additionally, transgenic 
(J) and wild-type (I) EDL muscle 
stained for laminin shows that 
despite enhanced laminin binding 
activity of transgenic muscle, laminin 
concentration in the extracellular 
matrix is not altered. 
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Figure 3-3) Muscle function is similar in both wild-type and MCK-LARGE 
transgenic mice. EDL and soleus muscles (n=6) were dissected from wild-type 
and transgenic animals of 31-32 weeks of age.  Neither the mass of the EDL nor 
the soleus muscle of transgenic animals differed significantly from that of wild-
type littermates (A).  Similarly, contractile measurements performed in vitro 
demonstrated that transgenic EDL and soleus muscles generated maximal 
forces similar that observed in wild-type muscle (B).  However, specific forces 
calculated for each muscle revealed that for both the EDL and soleus muscle, 
specific forces were lower in transgenic animals than those measured in wild-
type muscle (C).  Body weight was not significantly different between wild-type 
and transgenic animals (D).  Data are presented as means ± SEM.  
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Figure 3-4) Fast-twitch muscle in MCK-LARGE animals is protected from 
contraction-induced injury.  Contraction-induced injury was performed in vitro 
by subjecting EDL and soleus muscle from either wild-type or transgenic 
littermates (line 1) of 31-32 weeks of age to a series of 5 lengthening 
contractions of 30% strain.  Force deficits measured in the EDL were consistently 
lower in MCK-LARGE muscle as compared to wild-type and were significantly 
different after the first and second contractions.  Force deficits measured in the 
soleus muscle were not different between the two genotypes.  Force deficit was 
calculated as the difference in maximal force production immediately prior to and 
following each contraction and expressed as a percentage of maximal force 
production.   
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CHAPTER 4 
 
Muscle-specific expression of LARGE restores neurotransmission  
deficits in LARGEmyd mice 
 
ABSTRACT 
Mutations in several glycosyltransferases underlie a group of muscular 
dystrophies known as glycosylation-deficient muscular dystrophy.  A common 
feature of these diseases is loss of glycosylation and consequent dystroglycan 
function that is correlated with severe pathology in muscle, brain, and additional 
tissues.  While glycosylation of dystroglycan is essential for function in skeletal 
muscle, whether glycosylation-dependent function of dystroglycan is sufficient to 
explain all complex pathological features associated with these diseases is less 
clear. Dystroglycan glycosylation is impaired in LARGEmyd mice as a result of a 
mutation in like-acetylglucosaminyltransferase (LARGE), a putative 
glycosyltransferase known to cause muscle disease in humans.  We generated 
animals with restored dystroglycan function exclusively in skeletal muscle by 
crossing LARGEmyd animals to a recently created transgenic line that expresses 
LARGE selectively in differentiated muscle.  Transgenic LARGEmyd mice were 
indistinguishable from wild-type littermates and demonstrated a complete 
amelioration of muscle disease as evidenced by an absence of muscle 
pathology, restored contractile function, and a reduction in serum creatine kinase 
activity.  Moreover, while deficits in nerve conduction and neuromuscular 
transmission were observed in LARGEmyd animals, these deficits were fully 
rescued by muscle-specific expression of LARGE and resulted in restored 
74 
 
structure of the neuromuscular junction.  These data demonstrate that impaired 
neurotransmission contributes to muscle weakness in LARGEmyd mice and that 
the noted defects are primarily due to the effects of LARGE in stabilizing the 
endplate of the neuromuscular junction. 
INTRODUCTION 
The muscular dystrophies are a heterogeneous group of genetic diseases 
characterized by muscle degeneration, progressive weakness, and often a 
reduced lifespan.  Several severe forms of muscular dystrophy, such as Walker-
Warburg Syndrome (WWS) or Muscle-eye-brain disease (MEB) can also include 
hypotonia, mental retardation and eye malformations (204).  WWS, MEB, 
Fukuyama CMD, MDC1C and several forms of milder limb-girdle muscular 
dystrophy (LGMD 2I, 2K, 2M, 2N) share a defect in the post-translational 
processing of the cell surface protein dystroglycan, and are sometimes termed 
“dystroglycanopathies” (141).  Dystroglycan is encoded by the DAG1 gene, 
producing a single polypeptide sequence that is cleaved to form two functional 
subunits (α and β) which remain associated at the plasma membrane (159).  α-
dystroglycan is heavily glycosylated and functions as a receptor for several 
components in the extracellular matrix including laminin (12, 191), agrin (137), 
and neurexin (189).   α-dystroglycan is anchored to the extracellular face of the 
plasma membrane through its non-covalent association with β-dystroglycan, a 
type I membrane protein (160).  β-dystroglycan, in turn, binds to dystrophin and 
the rest of the dystrophin glycoprotein complex, thereby creating a 
transmembrane link that is critical for dystroglycan function.  In order to function 
as an extracellular matrix receptor, glycosylation of α-dystroglycan is essential 
and has been shown to be reduced or completely absent in tissues of 
dystroglycanopathy patients (21).  Mutations in the DAG1 gene are rare and 
nearly all causative mutations that result in disease have been identified in genes 
thought to encode glycosyltransferases (156).  Consequently, these mutations 
abolish the function of dystroglycan as a receptor for extracellular ligands in the 
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various tissues where dystroglycan is expressed which is thought to underlie the 
broad clinical spectrum observed in patients. 
In addition to dystrophin, dystroglycan associates with other proteins 
within the dystrophin-glycoprotein complex (DGC), and mutations in a number of 
DGC components have been shown to disrupt the normal assembly or function 
of the entire complex, resulting in multiple forms of muscular dystrophy.  Muscle 
fibers undergo a significant degree of mechanical stress and the DGC is 
hypothesized to function, at least in part, in the stabilization the sarcolemma 
during cycles of contraction and relaxation (12).  Within the DGC, dystroglycan 
functions as a transmembrane bridge between the basal lamina surrounding 
each muscle fiber (22), via binding laminin, and the intracellular cytoskeleton, 
through associations with dystrophin, thereby providing structural support to the 
sarcolemma.  While the importance of this complex in skeletal muscle is 
unequivocal, dystroglycan is ubiquitously expressed and its functions in non-
muscle tissues are not as well understood. 
The targeted gene deletion of dystroglycan is embryonic lethal (23) and 
several studies have utilized tissue-specific deletions to dissect discrete functions 
of dystroglycan in neural cell types.  Dystroglycan is expressed in a specialized 
DGC in Schwann cells of peripheral nerves (205, 206) where it can serve as a 
receptor for both laminin (207) and agrin (208).  Schwann cell specific deletion of 
dystroglycan leads to the development of a progressive neuropathy as evidenced 
by reduced nerve conduction velocity, altered structure and reduced staining of 
voltage-gated sodium channels at nodes of Ranvier, and dysmyelination defects 
(133).  Dystroglycan is also expressed at the neuromuscular junction (NMJ), and 
mice chimeric for deletion of dystroglycan demonstrate impaired 
organization/structure of NMJs (209).  Agrin is an essential organizer of the NMJ 
during muscle development  and although dystroglycan can serve as an agrin 
receptor in muscle, interactions between agrin and dystroglycan are dispensable 
for acetylcholine receptor aggregation at the postsynaptic membrane during 
formation of this synapse (139, 210).  Rather, dystroglycan appears to function 
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both in the assembly of the synaptic basement membrane (140) and the 
localization of additional DGC components to the synapse (211) which contribute 
to maintenance of the synapse in adult muscle.    
While dystroglycan appears to have important functions in both peripheral 
nerve and the NMJ, whether these functions are dependent upon its ability to 
bind extracellular ligands is not well understood.  The LARGEmyd mouse model 
contains a mutation in the like-acetylglucosaminyltransferase (LARGE) gene 
(167, 168), a putative glycosyltransferase, and  display a muscular dystrophy 
similar to that observed in patients with LARGE mutations (194, 195).  The 
structure of the neuromuscular junction in LARGEmyd muscle is also impaired 
(144, 145), resembling defects observed in dystroglycan-null NMJs (209), and 
appears to be result from impaired NMJ maintenance rather than initial assembly 
(140).  Additionally, peripheral nerve conduction velocity is reduced in both 
LARGEmyd and the allelic variant LARGEenr animal model and coincides with 
defects in distal nerve myelination (145).  These data suggest that dystroglycan 
glycosylation is essential not only in skeletal muscle but also for peripheral nerve 
function and NMJ stabilization.  
We used muscle-specific overexpression of LARGE to rescue extracellular 
matrix receptor function of dystroglycan exclusively in LARGEmyd muscle to 
determine the degree to which dystroglycan glycosylation in non-muscle tissues 
contributes to the neuromuscular and muscle function in muscular dystrophy.  
Here we demonstrate that rescue of dystroglycan function exclusively in striated 
muscle is sufficient to rescue several symptoms of muscular dystrophy in 
LARGEmyd animals including amelioration of muscle pathology, restoration of 
force production, and extension of lifespan.  Furthermore, we demonstrate that 
structural defects at the neuromuscular junction and functional deficits in 
neuromuscular transmission observed in LARGEmyd mice can be completely 
restored via rescued glycosylation of dystroglycan in muscle fibers.      
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METHODS 
Animals. MCK-LARGE transgenic animals were generated previously on a 
C57BL/5 background (Chapter 3) and bred onto the LARGEmyd strain from our 
maintained colony.  Wild-type, TG-LARGEmyd, and LARGEmyd mice used for all 
experiments were age/sex-matched littermates aged 20-40 weeks unless 
otherwise noted.  Animals were housed in a specific pathogen free (SPF) barrier 
facility in the Unit for Laboratory Animal Medicine at the University of Michigan 
and all procedures were approved by the University of Michigan Committee for 
the Use and Care of Animals.   
Western Blotting. Tissues were removed from deeply anesthetized animals and 
immediately frozen on dry ice until further processing.  Samples of sciatic nerve 
were pooled from 5 mice per genotype.  All samples were minced and 
homogenized in a buffer containing TBS (120-150 mM sodium chloride, 50 mM 
Tris pH 7.5) and 1% Triton-X 100.  Samples were cleared via centrifugation and 
quantified using the DC Assay (Bio-Rad).  Wheat germ agglutin (WGA) 
enrichment was performed by incubating Triton-X lysates overnight with WGA-
conjugated sepharose (Vector Biolabs) at 4 degrees while rotating.  Beads were 
washed and protein was eluted in batch by incubating beads with a buffer 
containing 500 mM N-acetylglucosamine and 0.1% Triton-X 100 in TBS.  All 
buffers contained protease inhibitors (0.5 µg/ml Pepstatin A, 2 kallikrein inhibitor 
units/ml Aprotinin, 1 ug/ml Leupeptin, 0.4 mM PMSF, 0.6 mM Benzamidine).  
Samples were separated on 3-15% gradient polyacrylamide gels and transferred 
to polyvinylidene fluoride (PVDF) membrane (Millipore).  Immunoblotting was 
performed using a blocking/incubation buffer that contained 5% nonfat dry milk 
dissolved in TBS-T (TBS, 0.05% Tween-20).  Primary antibodies included a 
rabbit polyclonal antibodies to β-dystroglycan (Santa Cruz), and mouse 
monoclonal antibodies to the myc epitope (9E10, Sigma) and glycosylated α-
dystroglycan (IIH6, gift from Dr. Kevin Campbell).   
Immunofluorescent Microscopy and Histology. Brain samples were carefully 
removed, cut in half along the sagittal axis, and immediately frozen on a plastic 
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cover slip placed on dry ice.  Sciatic nerves were removed from deeply 
anesthetized animals and fixed overnight in 2.5% glutaraldehyde / 0.1M 
Cacodylate buffer, pH 7.4.  Samples were further processed by the Microscopy 
and Image Analysis Core (MIL) at the University of Michigan.  Muscles were 
dissected and mounted in OCT and immediately frozen in liquid nitrogen cooled 
isopentane.  Frozen samples were cut into 8 µm cross sections using a cryostat 
and stored at -80° until later being used for immunofluorescent microscopy or 
staining with hematoxylin and eosin.  For immunfluorescent staining, slides were 
rehydrated with PBS and blocked 1-2 hours in an incubation buffer containing 5% 
BSA in PBS.  Slides were incubated at room temperature with primary and 
secondary antibody for 1-2 hours each with 4 x 5 minutes washes of PBS in 
between incubations.  Final slides were mounted in Permafluor (Thermo 
Scientific) and imaged with an Olympus BX-51 fluorescence microscope.    
Creatine Kinase Activity.  Serum was collected from the saphenous vein of 
restrained animals and stored at -80 degrees.  Creatine kinase activity was 
measured in duplicate from 13-16 animals per genotype using CK NADP 
Reagent (RAICHEM).   
In Situ Contractile Function Measurements.   For in vitro measurements, the 
EDL and soleus muscles were carefully dissected from deeply anesthetized 
mice.  A 5-0 silk suture was tied to the proximal and distal tendons.  One tendon 
was tied to a servo motor (Aurora Scientific, model 300), the other to a force 
transducer (Kulite Semiconductor, model BG-50).  The muscle was bathed in 
Krebs mammalian Ringer solution maintained at 25°C and bubbled continuously 
with 95% O2 and 5% CO2 to stabilize pH at 7.4. The muscle was stimulated by 
square wave pulses delivered between two platinum electrodes connected to a 
high-power biphasic current stimulator (Aurora Scientific, model 701B) and 
controlled via an IBM–compatible personal computer and custom-designed 
software (LabVIEW 7.1, National Instruments, Austin, TX).  Pulses were 
delivered with increasing voltage until maximum isometric twitch was determined, 
at which muscle length was adjusted and optimal muscle length (Lo) was 
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determined. The Lo was measured with digital calipers and recorded.  Stimulus 
frequency was then increased until maximum isometric force (Po) was achieved.  
Muscles were held at Lo and subjected to trains of pulses to generate an 
isometric contraction (300 ms for EDL, 900 ms for soleus).  Cross sectional area 
was estimated by dividing the muscle wet mass (mg) by the product of fiber 
length (Lf, mm) and the density of mammalian skeletal muscle (1.06g/cm3).  
Specific force (sPo) was calculated by dividing Po by the total fiber cross-sectional 
area (CSA) for each muscle. A total of 3 mice and 6 muscles per genotype were 
tested between the ages of 27 and 31 weeks. 
Muscle Injury Protocol. Following measurement of maximum twitch force and 
Po, muscles were stimulated (100 ms for EDL, 300 ms for soleus) and held at Lo 
to allow muscles to develop Po.  Immediately following the isometric contraction, 
muscles were stretched through a 30% strain relative to Lf and a velocity of 1 
Lf/s.  Total stimulation time was 400 ms for EDL muscles and 600 ms for soleus 
muscles.  Muscles were then returned to Lo, and subjected to four additional 30% 
lengthening contractions, each with 12 seconds in between, for a total of 5 
stretches per muscle. The muscle was allowed to rest one minute and a final Po 
was measured.  The force generated after each stretch was recorded during the 
isometric contraction that immediately preceded the subsequent stretch.  Force 
deficit was calculated as the decrease in Po observed after each stretch as a 
percentage of Po measured prior to the first lengthening contraction.  A total of 3 
mice and 6 muscles per genotype were tested between the ages of 27 and 31 
weeks. 
In Situ Contractile Function Measurements. Contractile function in 
gastrocnemius muscle was measured in situ in anesthetized mice that were 
placed on a temperature-controlled platform warmed to 37 degrees.  The muscle 
was carefully dissected from the surrounding environment and a 4-0 silk suture 
was tied around the distal tendon that was subsequently severed and tied to the 
lever arm of a servo motor (model 305B, Aurora Scientific).  The hindlimb was 
tied securely to a fixed post at the knee.  A continuous drip of warmed saline was 
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administered to the muscle to maintain a temperature of 37 degrees for the 
entirety of the procedure.  A bipolar platinum wire electrode was used to directly 
stimulate the tibial nerve and optimal voltage, frequency and muscle length (Lo) 
were determined.  Muscle was then held at Lo and 300 ms trains of pulses were 
applied to determine maximum isometric tetanic contraction (Po). This process 
was repeated with the exception that a cuff electrode was placed around the 
proximal and distal ends of the muscle in order to stimulate the muscle.  When 
force measurements were completed, the muscle was removed and cross 
sectional area and specific force was calculated as described above.  A total of 5 
mice per genotype were tested between the ages of 20 and 40 weeks. 
Neuromuscular Junction Staining.  Sternocleidomastoid muscles were 
dissected from anesthetized animals and incubated in 1% paraformaledhyde for 
20 minutes at room temperature.  Muscles were then rinsed in PBS and 
incubated in 30% sucrose overnight at 4 degrees.  Muscle were mounted and a 
cryostat was used to generated 30 µm longitudinal sections.  Immunofluorescent 
staining was performed similar to that described above using α-bungarotoxin 
conjugated to AlexaFluor 488 (Invitrogen) and a rabbit polyclonal anti-
neurofilament antibody (Millipore). 
Nerve Conduction Velocity Measurements.  Mice were anesthetized with 
isofluorane (5% induction, 1-2% maintenance) and temperature was maintained 
at 34 degrees using a heat lamp.  Sterile electrodes were placed in the ankle and 
the dorsum of the foot.  Sural nerve conduction velocity (SNCV) was determined 
by antidromically stimulating at the ankle and recording at the foot.  SNCV was 
calculated by dividing the distance by the onset latency.  Sciatic-tibial motor 
nerve conduction velocity (SMNCV) was determined by placing recording 
electrodes at the dorsum of the foot and orthodromically stimulating at the ankle 
and sciatic notch.  SMNCV was calculated by dividing the distances between the 
onset latencies.  A total of 10 mice were tested per genotype between the ages 
of 20 and 40 weeks. 
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Tail Flick Assay.  Tail flick responses were measured using an adjustable red 
light emitter. The time it took for the mouse to move their tail after the beam was 
activated was recorded electronically. The light source was set at 25 °C and the 
temperature increased to 70 °C over the course of 10 seconds.  A threshold of 10 
seconds was applied to prevent injury to the mice.  A total of 6 mice were tested 
per genotype between the ages of 20 and 40 weeks. 
Rotarod Test.  Animals were tested using an Accelerating Rotarod (Economex, 
Columbus Instruments).  Mice were place on the rod and allowed to remain 
stationary for 10 seconds, after which the speed was set at 5 rpm.  After rotating 
at a constant speed for 60 seconds, the rod began accelerating at a rate of 0.1 
rpm/second and continued until the animal was unable to remain on the rod.  
Total time spent on the rod was recorded from the time the rod began rotating.  
Mice were given 3 trials daily for 5 consecutive days.  In between daily trials, 
animals were returned to their cage for a minimum of 15 minutes.  A total of 6 
animals were tested for each genotype between the ages of 22 and 30 weeks. 
Clasping Behavior.  Clasping behavior was scored blindly according to Guyenet 
et. al (212).  Briefly, animals of unknown genotype were suspended by the base 
of the tail for 10 seconds and the time each animal spent with one or both legs 
partially or completely retracted was used as the basis for a score between 0 
(unaffected) and 3 (severely affected).  A total of 10-16 mice per genotype were 
tested for each genotype.  LARGEmyd animals were 12-30 weeks whereas wild-
type and TG-LARGEmyd were as old as 62 weeks. 
RESULTS 
Muscle specific expression of LARGE-myc results in hyperglycosylation of 
dystroglycan in LARGEmyd skeletal muscle.  We generated a line of transgenic 
mice in that express human LARGE exclusively in striated muscle tissues 
through the use of a muscle creatine kinase (MCK) promoter/enhancer sequence 
(Chapter 3).  These mice demonstrate hyperglycosylation of dystroglycan in 
skeletal muscle concomitant with significantly enhanced laminin binding activity.  
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Transgenic MCK-LARGE animals demonstrated muscle-specific expression of 
the myc-tagged LARGE protein as evidenced by reactivity with the anti-myc 
9E10 antibody in whole lysates from both skeletal and cardiac muscle (Fig. 
4.1A).  LARGE-myc was not detected in non-muscle tissues including brain, 
spinal cord, and lung.  In order to reveal aspects of the disease in LARGEmyd 
mice that result from impaired dystroglycan function in non-muscle tissues, MCK-
LARGE transgenic mice were crossed onto the LARGEmyd strain to generate 
transgenic animals homozygous for the LARGE mutation.  Western blot analysis 
of WGA-purified lysates isolated from wild-type (WT), LARGEmyd (myd) and 
transgenic LARGEmyd (mydTG) animals demonstrated that the transgene was 
capable of glycosylating α-dystroglycan in LARGEmyd cardiac and skeletal muscle 
(Fig. 4.1B).  Staining with the glycosylation specific IIH6 antibody demonstrated 
that while glycosylation is absent in LARGEmyd tissues, tissues from TG-
LARGEmyd animals exhibited significant levels of glycosylation, above that 
observed in wild-type muscle.  Native dystroglycan runs as a broad band 
between 120 and 156 kDa and similar to what is observed in MCK-LARGE mice 
(Chapter 3), α-dystroglycan from TG-LARGEmyd muscle ran at a much higher 
molecular weight demonstrating that LARGE overexpression was capable of 
adding or extending additional glycans on α-dystroglycan.  Dystroglycan 
glycosylation was not detected in non-muscle tissues such as brain (Fig. 4.1C) or 
sciatic nerve (Fig. 4.1D) from LARGEmyd and TG-LARGEmyd mice confirming that 
the transgene was not active in these tissues.  Because LARGEmyd mice exhibit 
neuronal migration defects in the cerebellum (21), brain sections were stained to 
confirm that this defect was still present in transgenic LARGEmyd animals.  
Sagittal sections of cerebellum stained with IIH6 and DAPI demonstrated a lack 
of dystroglycan glycosylation in both LARGEmyd and TG-LARGEmyd brain (Fig. 
4.2A).  Additionally, groups of densely stained granule cells were detected in the 
molecular layer, indicating a neuronal migration failure during cerebellar 
development (Fig. 4.2B).  IIH6 stained gastrocnemius muscle sections from the 
same animals demonstrated that dystroglycan glycosylation was absent in 
LARGEmyd animals and restored at the sarcolemma in transgenic LARGEmyd 
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mice (Fig. 4.2C).  These data demonstrate that the LARGE transgene is able to 
selectively glycosylate and restore function to dystroglycan in skeletal muscle 
while non-muscle tissues remain impaired. 
Hyperglycosylation of skeletal muscle dystroglycan in LARGEmyd mice 
ameliorates muscle disease.  LARGEmyd mice demonstrate a progressive 
muscle disease characterized by ongoing cycles of muscle degeneration and 
regeneration and an increase in fibrosis as a result of impaired interactions with 
the extracellular matrix that predispose the muscle to contraction-induced injury 
(22, 168).  Therefore, we hypothesized that the selective rescue of dystroglycan 
function in differentiated muscle would restore interactions with the extracellular 
matrix that serve to protect skeletal muscle from mechanical injury.  Hematoxylin 
and eosin stained gastrocnemius sections showed that while LARGEmyd muscle 
exhibited several parameters of muscle pathology including fibers of 
heterogeneous size, infiltration of inflammatory cells, and multiple regenerating 
fibers, muscle from TG-LARGEmyd animals was indistinguishable from wild-type 
muscle (Fig. 4.3A).  In addition to decreased histological signs of dystrophy, TG-
LARGEmyd mice also displayed a marked reduction in fibers containing 
internalized nuclei, which indicated a reduction in fibers undergoing regeneration 
(Fig. 4.3B).  Because muscle pathology was not evident, we hypothesized that 
TG-LARGEmyd animals would also have lower levels of serum creatine kinase 
activity.  While creatine kinase activity was nearly 3-fold higher in LARGEmyd 
animals compared to wild-type levels, expression of LARGE in skeletal muscle 
was sufficient to reduce creatine kinase activity to levels of wild-type littermates 
(Fig. 4.3C).  Additionally, although LARGEmyd mice begin to lose significant 
muscle mass in the later stages of life as a consequence of muscle wasting (Fig. 
4.7B), TG-LARGEmyd animals continued to gain weight similar to wild-type 
littermates (Fig. 4.3D). 
 To confirm that muscle-specific overexpression of LARGE in LARGEmyd 
mice rescued muscle function, soleus and extensor digitorum longus (EDL) 
muscles were used to assess muscle contractile function in vitro. Consistent with 
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our previous report (Chapter 2), soleus and EDL muscles from LARGEmyd 
animals demonstrated a reduction in both absolute and specific force production 
(Fig. 4.4A).  Additionally, total force production in both TG-LARGEmyd EDL and 
soleus muscle was fully restored to values similar to those measured in wild-type 
littermates.  Specific force values calculated for EDL muscle of LARGEmyd mice 
was approximately 63% of that measured in wild-type animals.   While specific 
force measured in TG-LARGEmyd EDL muscle was significantly higher than that 
measured in LARGEmyd animals, this value was approximately 85% of that 
measured in wild-type animals.  This appeared to be due to an elevation in mass 
of TG-LARGEmyd EDL muscle that did not result in an equivalent increase in total 
force production (data not shown).  Although specific forces measured in the 
soleus muscle were significantly reduced in LARGEmyd animals, TG-LARGEmyd 
values were fully rescued and not different from values measured in wild-type 
muscle.  
We previously demonstrated that LARGEmyd muscles composed of 
predominantly fast-twitch fibers are highly susceptible to contraction-induced 
injury as a result of impaired interactions between dystroglycan and laminin (48).  
We hypothesized that restoration of dystroglycan glycosylation specifically in 
skeletal muscle would be sufficient to restore extracellular matrix receptor 
function and reduce the susceptibility of LARGEmyd muscle to contraction-
induced injury.  Muscle injury was performed by subjecting EDL and soleus 
muscles to a series of 5 lengthening contractions of 30% strain in vitro.  In 
agreement with our previous study, force deficits were significantly greater in 
LARGEmyd EDL muscle than in wild-type muscle after each successive 
lengthening contraction.  After 5 lengthening contractions, force production in 
LARGEmyd EDL muscle was roughly 20% of the value measured prior to injury 
(Fig. 4.4C).  In contrast, force deficits measured in TG-LARGEmyd EDL muscle 
were no different than values measured in wild-type muscle after each 
lengthening contraction.     
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 In addition to significant improvements in function, expression of the 
LARGE transgene in LARGEmyd mice also dramatically improved the health of 
LARGEmyd animals and restored breeding capacity.  While LARGEmyd animals in 
our colony rarely survive past 40 weeks of age, transgenic LARGEmyd are 
presently as old as 70 weeks (Fig. 4.7A).  Additionally, TG-LARGEmyd animals do 
not demonstrate the hindlimb clasping behavior exhibited by LARGEmyd 
littermates (Fig. 4.7C).  Because glycosylation of dystroglycan remains impaired 
in the central and peripheral nervous system of transgenic LARGEmyd animals, 
we next wanted to assess motor performance in the absence of muscle disease. 
Transgenic LARGEmyd mice do not demonstrate deficits in neuronal 
function. Deficits in motor coordination as a result of either impaired cerebellar 
architecture or deficits in peripheral nerve function were first tested using an 
accelerating rotarod protocol.  Animals were placed on a stationary rod and the 
time each animal was able to remain on the rod once it began rotating was 
recorded daily for 5 consecutive days.  On each day, fall latencies were 
significantly reduced in LARGEmyd animals but were not different between TG-
LARGEmyd and wild-type animals (Fig. 4.5A).  Additionally, all three genotypes 
were able to significantly increase the amount of time they spent on the rod by 
day 5.  Although TG-LARGEmyd demonstrated impaired cerebellar development 
(Fig. 4.2B), these results suggest that the defect does not significantly affect 
motor function or task learning since the performance of TG-LARGEmyd animals 
was not difference from wild-type mice.   
Deficits in nerve structure and function have been reported in both 
LARGEmyd mice and an additional strain containing a mutation in LARGE, which 
suggests that dystroglycan glycosylation is required for normal peripheral nerve 
function (145, 213).  Therefore, we wanted to determine whether TG-LARGEmyd 
mice similarly demonstrated impaired nerve function as a consequence of 
disrupted dystroglycan glycosylation in neuronal tissues.  A tail flick assay was 
performed which measures the ability of an animal to respond to a heated light 
beam stimulus focused on the tail.  As expected, time latencies measured in 
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LARGEmyd animals were significantly longer than those measured in wild-type 
animals.  Values obtained for TG-LARGEmyd animals however, were similar to 
wild-type (Fig. 4.5B).  Because performance during a tail flick assay can be 
dependent upon both nerve and muscle function, we wanted to assess nerve 
function independently.  Although conduction velocity measured in the sural 
nerve was not different between the three different genotypes (not shown), 
sciatic motor nerve conduction velocity was significantly reduced only in 
LARGEmyd animals (Fig. 4.5C).  However, semi-thin stained sections of sciatic 
nerve did not identify any pathological defects in myelination in either 30-week 
old LARGEmyd or TG-LARGEmyd animals (Fig. 4.8).   
Neurotransmission deficits present in LARGEmyd animals are restored in 
TG-LARGEmyd mice.  Neuromuscular junction structure is disrupted in 
LARGEmyd and DG-deficient muscle (144, 209).  Although dystroglycan is an 
agrin receptor, interactions with agrin are dispensable during formation of the 
neuromuscular junction and instead, dystroglycan is hypothesized to function in 
the maintenance and stabilization of the synapse (140, 214).  Because the 
neuromuscular junction is formed from both presynaptic and postsynaptic 
components, we investigated whether rescue of sarcolemmal dystroglycan 
function was sufficient to restore NMJ architecture in transgenic LARGEmyd mice.  
Alexa-488 conjugated α-bungarotoxin and an antibody to neurofilament were 
used to label presynaptic and postsynaptic regions of NMJs in whole-fixed 
sternocleidomastoid muscles.  NMJs in wild-type muscle exhibited the 
characteristic pretzel shape while this structure in LARGEmyd muscle was 
fragmented in appearance, consistent with previous studies (144) (Fig. 4.6A).  
However, expression of full length LARGE was sufficient to restore NMJs in TG-
LARGEmyd muscle so that they were indistinguishable from those in wild-type 
muscle.  This suggests a critical importance of sarcolemmal dystroglycan, as 
opposed to dystroglycan expressed in either presynaptic neurons or perisynaptic 
Schwann cells, for normal maintenance of NMJ structure.  In order to address the 
functional consequence of impaired NMJ structure in LARGEmyd mice, a 
contractile protocol was performed that utilized paired measurements of force 
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production in the gastrocnemius muscle.  This allowed for comparisons to be 
made in each muscle between maximum forces produced following stimulation to 
either the sciatic nerve or to the muscle directly.  If neurotransmission was 
impaired, direct muscle stimulation would produce higher maximal force values 
than when the muscle was stimulated via the nerve.  Consistent with observed 
measurements in the EDL and soleus muscle, specific force values measured in 
LARGEmyd gastrocnemius muscle were significantly lower than wild-type and 
transgenic LARGEmyd values (Fig. 4.6B).  Additionally, while forces measured 
during direct muscle stimulation were slightly lower than values obtained 
following nerve stimulation in wild-type animals, the opposite was observed in all 
LARGEmyd animals.  Direct stimulation of LARGEmyd muscle resulted in a mean 
16% increase in maximal force production compared to values measured during 
nerve stimulation (Fig. 4.6C).  However, no such increase was measured in 
transgenic LARGEmyd muscle, likely due to improved NMJ structure.  These 
results suggest that aberrant structure of the neuromuscular junction as a 
consequence of impaired dystroglycan function causes a functional denervation 
in muscle fibers, and that restoration of dystroglycan function at the postsynaptic 
membrane of skeletal muscle alone is sufficient to restore these functional 
defects in neurotransmission.  
DISCUSSION 
Although muscle disease is the prominent and shared feature of all 
muscular dystrophies, patients with mutations in glycosyltransferases also suffer 
from severe central and peripheral nervous system impairments as a result of 
disrupted dystroglycan function (150, 151, 194, 215).  Several studies have 
highlighted the importance of glycosylation-dependent interactions between 
dystroglycan and laminin at the sarcolemma that are important for providing 
critical structural support during muscle contractions (22, 216).  Disruption of this 
mechanical link can result in a high susceptibility to contraction-induced damage 
and is hypothesized to underlie the eventual decline in muscle function observed 
in DGC-related muscular dystrophies.  However, dystroglycan is ubiquitously 
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expressed and a mechanical role for the DGC in non-muscle tissue is less 
apparent.   
Here we demonstrate that muscle-specific restoration of the ligand binding 
activity of dystroglycan rescues several features of muscular dystrophy in 
LARGEmyd animals.  Overexpression of MCK-LARGE in LARGEmyd muscle 
resulted in significant hyperglycosylation of sarcolemmal α-dystroglycan beyond 
that observed in wild-type animals, reestablishing dystroglycan as an 
extracellular matrix receptor in skeletal muscle.  This resulted in a complete 
attenuation of muscle pathology in LARGEmyd animals and coincided with a 
recovery of muscle contractile performance.  Additionally, we observed that 
restored function of dystroglycan at the motor endplate was sufficient to restore 
normal NMJ architecture and this corresponded to a functional rescue of 
neurotransmission deficits observed in LARGEmyd animals.  These results 
suggest that muscle weakness observed in LARGEmyd mice as a consequence of 
primary muscle dysfunction is compounded by a failure in neurotransmission.  
LARGEmyd muscle demonstrates altered structure of the neuromuscular 
junction and our results demonstrate that this defect can also be reversed via 
selective restoration of dystroglycan function at the sarcolemma.  Although 
dystroglycan is a glycosylation-dependent agrin receptor (137) and can bind 
rapsyn (217), interactions with these critical NMJ proteins are not thought to be 
essential for initial formation of the neuromuscular junction.  Instead, 
dystroglycan and the DGC that is present at the NMJ appear to function in NMJ 
maintenance in adult muscle by contributing to the formation of the surrounding 
basal lamina and serving as a scaffold for additional proteins (211).  Because the 
structure of the NMJ is more disrupted in LARGEmyd  animals than in other mouse 
models of muscular dystrophy (144) this suggests that the altered structure is not 
simply a product of degenerating muscle but rather due to the distinct 
requirement of glycosylated dystroglycan in this structure.  
In addition to an amelioration of muscle dysfunction, an overall increase in 
health was observed that included improvements in longevity.  While the cause 
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of death is unknown in LARGEmyd mice, severe muscle weakness/paralysis 
leading to failure of food intake and cardiomyopathy (216) may contribute.  
Unexpectedly, a complete recovery of motor performance was also observed in 
TG-LARGEmyd animals despite evidence of impaired cerebellar and brain 
development that was not rescued by the transgene.  Because the cerebellum 
and motor cortex participate in the coordination of balance and movement, the 
functional consequence of defective neuronal migration in TG-LARGEmyd animals 
was tested using an accelerating rotarod.  Ordinarily, comparisons between wild-
type and LARGEmyd animals using this assay would be confounded by the 
profound muscle weakness present in LARGEmyd animals.  However, because 
muscle function was restored in TG-LARGEmyd animals and was comparable to 
wild-type mice, comparisons were able to be made with wild-type mice.  
Surprisingly, no differences in performance were detected and both groups of 
animals were able to improve significantly over the five day period.  Although 
LARGEmyd mice performed poorly, they were also able to improve their 
performance by the fifth day.  These results suggest that despite defects in 
cerebellar architecture, motor learning and coordination is not severely impaired 
in LARGEmyd animals. 
Deficits in rotarod performance have been documented in a Schwann-cell 
specific deletion of dystroglycan, which also demonstrates defects in myelination 
and conduction velocity (133).  In a related model of LARGE deficiency, 
conduction velocity in the sciatic nerve was reduced and coincided with the 
presence of large clusters of unmyelinated axons in the nerve (145).  In order to 
determine whether these same defects existed in LARGEmyd animals, sciatic 
nerves were collected from 40-week old animals.  Because electron microscopy 
did not reveal any differences between the three genotypes (not shown), this 
suggests that the nerve defect is either not 100% penetrant in all animals or is 
variable along the length of the nerve and missed in our analysis.  Nerve 
conduction velocity was measured in both sciatic and sural nerves, and deficits 
were only observed in sciatic nerves of LARGEmyd animals while sural conduction 
velocity was not different between the three genotypes.  Because peripheral 
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nerve function appeared normal in TG-LARGEmyd animals, despite evidence 
demonstrating that dystroglycan was hypoglycosylated, these data suggest that 
LARGE-mediated glycosylation of dystroglycan is not essential for normal 
peripheral nerve function.  While this conflicts with several studies demonstrating 
the importance of interactions between dystroglycan and laminin in myelination of 
peripheral nerves (218-220), not all nerve defects reported in DG-null animals 
are consistent with the exclusive glycosylation-dependent function of 
dystroglycan in the PNS.  LARGEenr animals do not demonstrate the defects in 
node elongation and sodium channel clustering that have been reported for 
Schwann cell specific dystroglycan-null animals (133, 145) which suggests that 
the formation of axonal nodal domains does not require glycosylation of 
dystroglycan by LARGE. 
In order to verify the tissue specific nature of the promoter, multiple tissues 
were stained for LARGE-myc protein expression and the transgene was not 
detected in either wild-type or transgenic non-muscle tissues.  Because α-
dystroglycan is capable of being cleaved and can be detected in serum (221), we 
also confirmed that hyperglycosylated dystroglycan was restricted to striated 
muscle tissues of TG-LARGEmyd animals, and reactivity with the glycosylation 
specific IIH6 antibody was not detected in neuronal tissues.  Additionally, 
neuronal migration defects were observed in the cerebellum of transgenic 
LARGEmyd animals which confirmed that functional deficits caused by impaired 
dystroglycan glycosylation in non-muscle tissues (222) were still present in 
transgenic LARGEmyd animals.  Therefore, absence of neuronal defects in 
transgenic LARGEmyd mice is not explained by expression of the transgene 
resulting in residual glycosylation of dystroglycan in neuronal tissues.  
An interesting explanation that might account for the observed rescue of 
nerve function may be related to the improvement in either muscle function or 
restored structure of the neuromuscular synapse.  While we observed a deficit in 
nerve conduction velocity of LARGEmyd sciatic nerve, sural nerve function was 
not different from wild-type animals.  If the impaired muscle function of LARGEmyd 
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animals negatively influenced motor neuron function, this might explain impaired 
conduction velocity in the motor sciatic nerve but not in the sensory sural nerve.  
Maintenance of neuronal connections can be dependent upon target-derived 
retrograde signals such as neurotrophins (223).  Skeletal muscle is a source of 
several neurotrophins including brain-derived neurotrophic factor (BDNF), NT-3, 
NT-4 and glia-derived neurotrophic factor (GDNF) (224-228) which may 
contribute to motor neuron survival and/or differentiation (229).  There is also 
evidence to suggest that expression of neurotrophins and their receptors might 
be altered in muscular dystrophy (230, 231). While it is intriguing to speculate 
that disruptions in neurotrophin related signaling may contribute to muscle 
weakness in muscular dystrophy, this hypothesis remains to be addressed. 
In this study, we demonstrate via selective restoration of dystroglycan 
function in skeletal muscle that extracellular matrix function of dystroglycan in 
cardiac and skeletal muscle is sufficient to ameliorate several characteristics of 
muscular dystrophy.  Additionally, we show that structural defects reported at the 
LARGEmyd neuromuscular junction result in a functional deficit in 
neurotransmission as a result of impaired sarcolemmal dystroglycan function.  
Because we no longer observe deficits in peripheral nerve function, we 
hypothesize that impaired function of dystroglycan in skeletal muscle may cause 
reciprocal deficits in nerve function as a consequence of either impaired 
communication at the neuromuscular junction or through retrograde signaling 
from diseased myofibers.  
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Figure 4-1) Selective expression of LARGE-myc in striated muscle results 
in hyperglycosylation of α-dystroglycan in LARGEmyd mice. Triton-X whole 
lysates from wild-type (WT) and transgenic MCK-LARGE (TG) mice stained with 
the 9E10 anti-myc antibody demonstrate LARGE-myc expression exclusively in 
skeletal and cardiac muscle (A, upper panel).  Equal loading of the gel is 
indicated by Ponceau S staining of the blot prior to immunostaining (A, lower 
panel).  WGA-enriched lysates demonstrate a loss of α-dystroglycan 
glycosylation in LARGEmyd (myd) animals as evidenced by a lack of reactivity 
with the glycosylation specific IIH6 antibody (B,C,D, upper panels).   Expression 
of the LARGE-myc transgene in LARGEmyd mice (mydTG) results in 
hyperglycosylation of α-dystroglycan selectively in cardiac and skeletal muscle 
(25 µg per lane) as demonstrated by a dramatic increase in molecular weight of 
the α-dystroglycan.  Glycosylation of α-dystroglycan was absent in brain (75 µg 
per lane) and sciatic nerve (60 µg) of LARGEmyd transgenic animals owing to the 
lack of transgene expression in these tissues.  In contrast to altered glycosylation 
of α-dystroglycan between the three different genotypes, expression levels of 
dystroglycan was unaltered as evidenced by similar reactivity with an anti-β-
dystroglycan antibody using stripped blots (B,C,D, lower panels).   
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Figure 4-2) Transgenic LARGEmyd mice demonstrate absence of functional 
dystroglycan in non-muscle tissue. Parasagittal sections of cerebellum from 
wild-type (left), LARGEmyd (middle) and transgenic LARGEmyd (right) stained with 
IIH6 demonstrate that only wild-type brain expresses glycosylated dystroglycan 
(A).  Absence of glycosylation in LARGEmyd and transgenic LARGEmyd 
cerebellum resulted in neuronal migration failure during development as 
indicated by densely stained DAPI stained cells (white arrows) within the 
molecular layer (B).  Although abnormal dystroglycan glycosylation and function 
in the cerebellum was evident in both LARGEmyd and transgenic LARGEmyd 
brains, skeletal muscle from transgenic LARGEmyd animals contained 
glycosylated dystroglycan at the sarcolemma (C). 
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Figure 4-3) Muscle disease is ameliorated in transgenic LARGEmyd animals. 
Hematoxylin and eosin stained skeletal muscle sections demonstrate 
amelioration of dystrophy when the MCK-LARGE transgene is expressed in 
LARGEmyd muscle as indicated by an absence of inflammatory cells and a 
normalization of fiber size (A).  Muscle sections co-stained with the anti-laminin 
L-9393 antibody and DAPI demonstrate restoration of normal muscle architecture 
and a dramatic reduction in fibers undergoing degeneration or regeneration as 
indicated by a reduction in fibers with internalized nuclei (B).  Plasma creatine 
kinase levels were significantly reduced in transgenic LARGEmyd mice compared 
to LARGEmyd animals (n = 13-16 mice) (C).  Although body weights of LARGEmyd 
animals were significantly reduced due to the progressive loss of muscle mass, 
weights of transgenic LARGEmyd were not different from wild-type animals (D). 
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Figure 4-4) Muscle function is 
improved in transgenic LARGEmyd 
mice.  Contractile function of EDL 
and soleus muscle was measured in 
vitro (n=6 muscles).  While force 
production in both LARGEmyd EDL 
and soleus muscle was significantly 
reduced compared to wild-type, 
values for transgenic LARGEmyd 
muscles were not different from wild-
type (A).  Although expression of the 
transgene in LARGEmyd muscle 
resulted in a significant improvement 
in specific force, values for 
transgenic LARGEmyd EDL were 
below that of wild-type muscle (B).  
Contraction-induced injury was 
performed by subjecting EDL 
muscles to a series of lengthening 
contractions of 30% strain.  
LARGEmyd muscle demonstrated an 
elevated susceptibility to contraction-
induced damage as indicated by an 
increase in force deficit following 1, 
2, and 5 lengthening contractions 
compared to wild-type muscle (C).  
Muscles from transgenic LARGEmyd 
animals did not display a 
susceptibility to injury any more so 
that wild-type animals following 2 
and 5 lengthening contraction.   
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Figure 4-5) Neuronal function is improved in transgenic LARGEmyd animals.   
Motor coordination was tested using an accelerating rotorod.  Animals (n= 6 per 
genotype) were placed on a stationary rod that rotated at a constant speed of 5 
rpm for 60 seconds and began accelerating at a rate of 0.1 rpm/second.  The 
time each animal was able to stay on the rod beginning at rotation onset was 
recorded for 3 daily trials over 5 days.  Wild-type and transgenic LARGEmyd 
managed to stay on significantly longer than LARGEmyd mice during each trial 
and values measured for each trial were not statistically different from one 
another (A).  Each data point is representative of the mean latency for all mice of 
each genotype.  A tail flick assay was used to assess whether neurological 
dysfunction was evident in LARGEmyd and transgenic LARGEmyd animals.  Tail 
flick responses (n= 6 animals per genotype) were measured as the time it took 
for each mouse to remove their tail from a heated beam of light.  Only LARGEmyd 
animals demonstrated a significant delay compared to control animals (B).  
Nerve conduction velocity was measure in sciatic nerve (n = 10 animals per 
genotype).  Values measured in LARGEmyd animals were significantly slower 
while values in transgenic LARGEmyd were not different from values recorded in 
wild-type littermates (C).  Error bars for all graphs indicate SEM. 
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Figure 4-6) Neuromuscular junction structure and neurotransmission 
defects are restored in transgenic LARGEmyd mice.  Sternocleidomastoid 
muscles were fixed whole to stain the presynaptic and postsynaptic regions of 
the neuromuscular junction.   Acetylcholine receptors were labeled with Alexa488 
conjugated α-bungarotoxin (green) and an antibody to neurofilament (red) was 
used to label the motor neuron.  Representatives images of NMJs in wild-type 
and transgenic LARGEmyd muscle demonstrate the characteristic pretzel shape 
whereas NMJs in LARGEmyd muscle appear abnormal and fragmented (A).  To 
determine the functional consequence of disrupted NMJ structure, force 
production of gastrocnemius muscle was measured in situ and stimulated by 
either the tibial nerve or directly using a cuff electrode surrounding the muscle.  
Specific force values measured following muscle stimulation were always slightly 
lower than those measured after nerve stimulation for each wild-type and 
transgenic LARGEmyd animal (n= 4-5 animals per genotype) (B).  In contrast, 
specific force values were always higher for LARGEmyd animals following direct 
muscle stimulation indicating a partial functional denervation of fibers.  The 
difference in specific force measured for either nerve or direct muscle stimulation 
is shown as a percentage of total specific force produced from nerve (C).   
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Figure 4-7) Restoration of dystroglycan glycosylation in skeletal muscle 
significantly improves overall health.  A survival curve depicts survival data 
from a LARGEmyd colony maintained by our lab with transposed survival data 
from the recently generated TG-LARGEmyd strain that are presently 70 weeks of 
age (A).  While LARGEmyd animals lose significant muscle mass in the later 
stages of life, TG-LARGEmyd mice gain weight comparable to wild-type littermate.  
Shown is a photograph of a 68 week-old TG-LARGEmyd mouse (top left), the 
oldest currently surviving in the colony, alongside a 33-week old LARGEmyd 
mouse (bottom right) (B).  LARGEmyd mice demonstrate an abnormal hindlimb 
clasping behavior that is also rescued in TG-LARGEmyd(C).  Mice were briefly 
suspended by the tail and a score from 0 to 3 was assigned according to severity 
(n= 10-16 mice). 
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Figure 4-8) Lack of pathology in 
LARGEmyd and TG-LARGEmyd 
sciatic nerve.  Although impaired 
conduction velocity was detected in 
the sciatic nerve of LARGEmyd 
animals, pathology was not evident. 
Toluidine blue stained semi-thin 
sections of sciatic nerve from wild-
type (WT), LARGEmyd(myd), and TG-
LARGEmyd (TG-myd) animals 
demonstrate the absence of 
myelination defects in LARGEmyd and 
TG-LARGEmyd mice. Scale bar 
represents 200 µm. 
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CHAPTER 5 
 
Conclusions and Future Directions 
 
Summary of Thesis Work  
The occurrence of muscle degeneration in what we now refer to as 
muscular dystrophy was first described nearly 150 years ago (232, 233).  Despite 
the identification of a genetic basis nearly 120 years later (28), the precise 
mechanism by which muscle progressively degenerates remains a fervent topic 
of scientific research.  Although muscular dystrophy can arise from mutations in 
any of several distinct genes, a subset of these diseases are defined by a 
common defect in the post-translational modification of dystroglycan, and the 
causative gene mutations have been identified in a group of 
glycosyltransferases.  This hypoglycosylation impairs the function of dystroglycan 
as an extracellular matrix receptor and consequently disrupts interactions with its 
multiple extracellular ligands.  The critical interaction between laminin and 
dystroglycan in skeletal muscle is thought to function in the preservation of 
sarcolemmal integrity.  Therefore, when the interaction of dystroglycan with the 
extracellular matrix is abnormally disrupted, micro-tears in the sarcolemma that 
occur as a consequence of normal muscle contraction are exacerbated and allow 
for an increased flux of ions and small molecules across the membrane.  The 
membrane tears and flux of ions are thought to disrupt normal homeostasis and 
eventually result in death of the myofiber.  The importance of the interaction of 
dystroglycan and matrix to normal muscle function was the basis for chapters 2 
and 3 which explored the physiological consequence of either reduced or 
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enhanced laminin binding activity of dystroglycan in skeletal muscle.  
Dystroglycan is ubiquitously expressed and can also serve as a receptor for the 
neural-derived ligands, agrin and neurexin.  Because patients with mutations in 
glycosyltransferases exhibit both progressive muscle disease in addition to 
severe neurological deficits, this suggests that dystroglycan has additional 
essential functions in non-muscle tissues.  Potential deficits in peripheral nerve 
function that result from dystroglycan hypoglycosylation and the effects of loss of 
dystroglycan function on motor performance were investigated in chapter 4.  
Taken together, the experiments described in this thesis have attempted to 
dissect the distinct functions of dystroglycan in different tissues as a means to 
understand how mutations affecting dystroglycan function ultimately result in a 
multi-system muscle disease.  The work described in the preceding chapters and 
summarized below support the overall hypothesis that LARGE-mediated 
glycosylation is essential for normal skeletal muscle function with distinct 
functions at the lateral membrane and at the neuromuscular junction. 
Chapter 2 described the functional and molecular consequences resulting 
from impaired dystroglycan glycosylation in both slow-twitch and fast-twitch 
muscles of LARGEmyd/myd mice.  While the partial reduction of dystroglycan 
glycosylation observed in heterozygous LARGEmyd/- mice was not sufficient to 
alter muscle function, homozygous LARGEmyd/myd mice demonstrated a marked 
reduction in specific force in both soleus and EDL muscles.  Additionally, 
although EDL muscles from LARGEmyd/myd mice were highly susceptible to 
lengthening contraction-induced injury, LARGEmyd/myd soleus muscle surprisingly 
showed no greater force deficit compared to wild-type soleus muscle even 
though the muscle demonstrated a significant reduction in laminin binding activity 
and dystrophic pathology.  Interestingly, soleus muscles were shown to display a 
markedly higher expression of β1-containing integrins compared with EDL and 
gastrocnemius muscles.  This suggests that β1-containing integrins play an 
important role as alternative matrix receptors that can protect muscles containing 
slow-twitch fibers from contraction-induced injury in the absence of dystroglycan 
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function.  More importantly, these results reveal that contraction-induced injury is 
a separable phenotype from the dystrophic pathology of muscular dystrophy. 
 To further determine the importance of dystroglycan glycosylation in 
skeletal muscle function, a novel transgenic mouse was created that directs the 
overexpression of LARGE exclusively in striated muscle through the use of a 
MCK promoter/enhancer sequence.  Chapter 3 outlined the experiments 
designed to test the hypothesis that overexpression of LARGE in skeletal muscle 
could enhance lateral connections between the sarcolemma and surrounding 
basal lamina to provide additional protection from lengthening contraction-
induced injury in otherwise normal muscle.  Skeletal muscle of MCK-LARGE 
transgenic mice demonstrated hyperglycosylation of dystroglycan that coincided 
with a significantly elevated laminin binding affinity compared to that of wild-type 
muscles.  More importantly, fast-twitch skeletal muscle from transgenic mice 
demonstrated enhanced protection from mechanical injury such that force deficits 
following injury were significantly lower than those measured in wild-type 
littermates. These results indicate that hyperglycosylation and enhanced function 
of dystroglycan via increased activity of the enzyme LARGE may be therapeutic 
not only in inherited glycosylation-deficient muscular dystrophy but also in 
acquired diseases or disability resulting from muscle injury.  
 Chapter 4 discussed the experiments used to dissect the glycosylation-
specific functions of dystroglycan at the neuromuscular junction and in peripheral 
nerve function.  MCK-LARGE animals were crossed onto the LARGEmyd strain to 
generate mice homozygous for the myd mutation with restored LARGE function 
exclusively in cardiac and skeletal muscle.   These TG-LARGEmyd animals 
displayed a successful rescue of skeletal muscle function as evidenced by a 
reduction in serum creatine kinase activity, restoration of normal muscle 
structure, suppression of muscle degeneration, and an increase in protection 
from contraction-induced injury.  Notably, structural defects observed at the 
neuromuscular junction in LARGEmyd/myd mice were corrected in transgenic 
LARGEmyd/myd animals and were correspondingly associated with the rescue of 
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neurotransmission and nerve conduction deficits.  These results demonstrate 
that skeletal muscle weakness in LARGEmyd/myd mice results from combined 
defects in both skeletal muscle and neuromuscular function.  Importantly, these 
data suggest that neuronal deficits associated with impaired dystroglycan 
function may be exacerbated by impaired muscle function and/or communication 
at the neuromuscular junction. 
 The results outlined in this thesis expand the current body of knowledge in 
regard to the importance of dystroglycan glycosylation in normal muscle function 
and motor performance.  Because dystroglycan is central to the DGC, these 
results have important implications for the mechanisms by which dystrophy 
results in additional forms of DGC-related muscular dystrophies and are 
therefore critical for the eventual design of therapeutics aimed at treating the 
disease.  The implications of these results will be discussed in greater detail in 
the remainder of this chapter and future experiments that can clarify the discrete 
functions of dystroglycan in both muscle and neuronal tissues will be highlighted. 
Implications and Future Directions 
Mechanical Functions of the Dystrophin-Glycoprotein Complex 
Within the dystrophin-glycoprotein complex, dystroglycan serves as an 
essential transmembrane link between dystrophin and laminin in an interaction 
that has largely been hypothesized to be mechanical in nature.  Consequently, 
mutations that affect the assembly or function of the complex are thought to 
cause a destabilization of the sarcolemma which can disrupt myofiber 
homeostasis and initiate a destructive signaling cascade leading to cell death.  
Support for this hypothesis comes from studies that have shown increased 
membrane permeability of dystrophic muscle concomitant with increased 
concentrations of intracellular calcium (6, 54).  Additionally, studies have cited 
the susceptibility of dystrophic muscle to injury induced by lengthening 
contractions as evidence for impaired sarcolemmal integrity in dystrophic muscle 
resulting from mutations in DGC components (4, 30, 36).  Although the results 
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obtained in EDL muscle and described in chapters 2 and 3 support this claim for 
a mechanical function of dystroglycan, the LARGEmyd soleus muscle was 
resistant to mechanical injury but still exhibited pathological features of muscular 
dystrophy.  These results demonstrate that susceptibility to damage is not an 
initiating step that is sufficient to cause the dystrophy and weakness observed in 
this muscle.   
While a lack of susceptibility of the soleus to mechanical injury has also 
been reported in other models of muscular dystrophy (39, 51, 234), an 
explanation that accounts for this result is lacking.  In contrast to mutations in 
either dystrophin or sarcoglycan, mutations affecting the glycosylation of 
dystroglycan do not alter the composition or expression level of the DGC and 
therefore, the defects observed in muscle are a direct consequence of impaired 
dystroglycan function.  Consequently, the observed lack of impaired sarcolemma 
integrity in soleus muscle of LARGEmyd mice suggests that the interaction 
between dystroglycan and laminin is dispensable as a means of providing 
membrane stability to myofibers within this muscle.  In support of this conclusion, 
an alternative laminin receptor, α7β integrin, was shown to be highly enriched in 
the soleus muscle which highlights the possibility that these two primary laminin 
receptors in skeletal muscle function in a fiber-type specific manner (Fig. 5.1).   
Surprisingly, the targeted deletion of α7 integrin was shown to be only mildly 
dystrophic and largely affected the myotendinous junction, though evidence of 
dystrophy was observed almost exclusively in the soleus muscle (94).  In a more 
recent study, integrin-deficient and dystroglycan-deficient EDL muscles were 
directly compared and though both muscles demonstrated deficits in force 
production, only the loss of dystroglycan function resulted in susceptibility to 
mechanical injury.   This led the authors to conclude that only the DGC was 
required for anchoring the basal lamina to the sarcolemma in order to provide 
protection from mechanical injury (22).  An important caveat of the study was that 
all experiments were performed in fast-twitch muscle.  Based on the observation 
that α7β1integrin is highly enriched in slow-twitch muscle, directly testing the 
susceptibility of α7 integrin-null soleus muscle to contraction-induced injury would 
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be a critical experiment to test the hypothesis that dystroglycan and α7β1integrin 
have fiber-type specific functions.  Integrin-deficient soleus muscle would be 
predicted to be more susceptible to contraction-induced injury than a comparable 
fast-twitch muscle such as the EDL.  Additionally, the contribution of integrins to 
the prevention of muscle injury in fast-twitch muscle could also be directly tested 
in LARGEmyd animals by overexpression of α7 integrin using either an adenovirus 
vector or by crossing LARGEmyd animals to the reported α7 integrin transgenic 
strain (97).  Increased expression of α7β1 integrin at the sarcolemma of fast-
twitch fibers concomitant with a protection from contraction-induced injury would 
support a fiber-type specific laminin receptor hypothesis.  
As a means to further understand the importance of dystroglycan 
glycosylation in skeletal muscle function, a novel transgenic was created in which 
dystroglycan was hyperglycosylated exclusively in skeletal and cardiac muscle.  
This resulted in a dramatic elevation in laminin binding activity and enhanced 
protection from contraction-induced injury as compared to normal muscle.  
Similar to the results obtained in LARGEmyd animals, this effect was only 
observed in the EDL muscle and force deficits measured in wild-type and MCK-
LARGE soleus muscle were not different.  Because neither the absence nor the 
enhanced affinity of dystroglycan for laminin in soleus muscle altered the 
susceptibility of the soleus muscle to mechanical damage, this suggests that 
interactions between laminin and dystroglycan do not play a significant role in 
preventing mechanical injury in this muscle type.  This is especially noteworthy in 
the context of human disease since the mouse soleus is more representative of 
human muscle (188).  Although LARGEmyd soleus muscle is resistant to 
mechanical injury, it is important to note that the muscle still demonstrates 
pathological features of muscular dystrophy, and this implies that sarcolemmal 
disruptions are not an initiating event leading to dystrophy in this muscle.  This 
result supports the hypothesis that the DGC has important non-mechanical 
functions in skeletal muscle that when impaired, contribute to muscle disease. 
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Non-Mechanical Functions of the Dystrophin-Glycoprotein Complex 
 Several reports have identified interactions between dystroglycan and 
known signaling and adaptor proteins but how impaired dystroglycan function 
affects cell signaling and whether or not altered intracellular signaling contributes 
to the dystrophic pathology is not well understood.  The c-terminal domain of β-
dystroglycan can bind the well known adapter protein Grb2 (103, 107) and also 
contains a tyrosine residue that when phosphorylated (108), can recruit several 
additional SH2-domain containing adaptor proteins (110).  Disruptions in cell 
signaling have also been hypothesized to be dependent upon the binding of 
dystroglycan to laminin.  In one example, the DGC has been shown to interact 
with subunits of heterotrimeric G proteins in a laminin-dependent manner (113) 
which might underlie the altered Ca2+ homeostasis observed in several forms of 
muscular dystrophy and originally attributed to membrane tears.  Additionally, the 
disruption of the laminin/dystroglycan interaction in vitro using antibodies against 
α-dystroglycan resulted in decreased AKT and GSK-3β activation and an 
increase in apoptotic cell death (112).  Notably, laminin-211 deficient dy/dy mice 
also had increased activation of apoptotic death pathways and it has been 
hypothesized that altered signaling may contribute to the dystrophic pathology in 
laminin-211 associated muscle disease (84, 87).  While the precise mechanism 
by which defects in dystroglycan result in impaired signaling is unclear, our 
results suggest that such signaling may be physiologically relevant and have 
significant implications for other DGC-associated dystrophies that lead to a 
concomitant reduction in dystroglycan expression at the sarcolemma.   
In light of these observations, it is important to note that while the 
hyperglycosylation of dystroglycan in fast-twitch muscles resulted in an enhanced 
protection from contraction-induced injury, a significant elevation in laminin 
binding activity may also affect potential laminin-mediated signaling pathways.  
Though deleterious effects as a result of dystroglycan hyperglycosylation in 
MCK-LARGE mice were generally not observed, muscles examined from these 
animals were slightly larger than wild-type littermates which resulted in a slight 
reduction in specific force as compared to wild-type animals.  However, since 
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body weights were not significantly different between the two genotypes, this 
suggests that the quality of force that is produced in muscles containing 
dystroglycan hyperglycosylation is somehow reduced.  This does not appear to 
result from any structural abnormalities in the muscle since histological 
examination did not detect any differences from wild-type muscle.  
Hyperglycosylation of dystroglycan and potential unidentified substrates of 
LARGE could cause an increase in fluid retention in the extracellular space 
contributing to an increase in mass without affecting force production.  However, 
ratios of wet mass to dry mass did not reveal differences between transgenic and 
wild-type muscle (not shown).  Because the DGC functions in the transmission of 
forces at the lateral membrane (128), it is possible that enhanced glycosylation of 
dystroglycan by LARGE can affect mechanisms of force production which might 
explain the observed reduction in specific force.  However, the lateral membrane 
is often the site of muscle injury in dystrophic muscle and because the transgene 
was capable of completely restoring susceptibility to muscle injury, this suggests 
that any defect at the lateral membrane has been corrected.  Further detailed 
examination of the muscle basal lamina and myotendinous junction structure by 
electron microscopy may lend some insight into the mechanisms underlying the 
slight loss of specific force production in MCK-LARGE mice.    
Since laminin-mediated increases in AKT signaling have been reported, 
this may warrant a deeper investigation into the effect of dystroglycan 
hyperglycosylation on muscle growth.  One possibility that remains to be tested is 
the importance of dystroglycan glycosylation during muscle regeneration.  The 
muscle-specific deletion of dystroglycan in skeletal muscle yielded an 
unexpected result in that while animals were dystrophic,  they were also much 
larger that littermate controls, demonstrating significant muscle hypertrophy as a 
consequence of retained dystroglycan function in satellite cells (101).  Because 
TG-LARGEmyd mice express functional LARGE only in differentiated muscle and 
not in muscle precursors, the importance of dystroglycan glycosylation in satellite 
cells could be tested using this animal model.   
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Although wild-type and TG-LARGEmyd animals did not demonstrate 
differences in response to contraction-induced injury when measured in isolated 
muscles in vitro, an in situ injury protocol could be used in order to determine 
whether the recovery from muscle injury, which requires the proliferation and 
differentiation of satellite cells, is abnormal.  As a means to test whether TG-
LARGEmyd animals demonstrate deficits in muscle regeneration as a 
consequence of impaired dystroglycan glycosylation in satellite cells, lengthening 
contractions could be performed in anesthetized mice using EDL muscle in a 
protocol similar to that used by Lockhart et al. (235).  This would allow for an 
immediate measurement of force production and force deficit following a 
lengthening contraction-induced injury.  Force production could also be 
measured at later time points (5-7 days post-injury) to determine whether the 
timeline for recovery of muscle function was prolonged in TG-LARGEmyd animals 
due to deficits in satellite cell function resulting from impaired dystroglycan 
glycosylation.  In parallel with these studies, a more severe muscle injury could 
be achieved using injection of either cardiotoxin or barium chloride.  Because 
cardiotoxin causes severe muscle injury and destroys local satellite cells, muscle 
regeneration in this model would require satellite cell proliferation and substantial 
cell migration into the injury site.  Alternatively, barium chloride destroys muscle 
fibers without harming the satellite cell pool and provides a milder model of 
muscle injury (236).  In order to quantify regeneration, injured muscle could be 
collected at multiple time points and the persistence of internalized nuclei and 
expression of muscle differentiation markers (myogenin, MyoD, Pax7) could be 
analyzed.  Reduced staining of proteins required for differentiation might suggest 
a critical function for LARGE-mediated glycosylation in satellite cell populations.  
If differences are observed, satellite cells could be isolated from LARGEmyd mice 
and the potential for proliferation, migration, and differentiation could be studied 
in vitro before and after LARGE overexpression.  An inability to recover from 
muscle injury similar to wild-type controls would highlight essential functions of 
dystroglycan glycosylation in the process of muscle regeneration that may 
contribute to muscle disease in cases of glycosyltransferase deficiency.    
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Dystroglycan Function in Neural Tissues 
In addition to being required for normal skeletal muscle function, tissue-
specific dystroglycan deletions have also demonstrated the importance of 
dystroglycan in neurological function (131, 133).  In order to understand the 
physiological consequences of impaired interactions between dystroglycan and 
its various ligands in neuronal tissues, TG-LARGEmyd mice were generated that 
have impaired dystroglycan function in all tissues except skeletal muscle.  
Animals exhibited an apparent amelioration of muscle pathology, allowing for 
more subtle physiological defects in other tissues to be assessed, the results of 
which were described in chapter 4 and outlined in figure 5.2. 
Dystroglycan was initially identified as a receptor for agrin in postsynaptic 
membranes isolated from the Torpedo electric organ (135).  Although 
dystroglycan can bind both neural and muscle-derived agrin, agrin-dependent 
clustering of acetylcholine receptors in the postsynaptic membrane during the 
formation of the neuromuscular junction (NMJ) does not require interactions with 
dystroglycan (138, 139).  Instead, dystroglycan is suspected to function in the 
maintenance of the NMJ which may be mediated by interactions with laminin in 
the synaptic basement membrane (140, 237).  Impaired structure of the NMJ has 
been reported in both dystroglycan-deficient (209) and LARGE-deficient muscle 
(144) which suggests that glycosylation of dystroglycan is critical for normal 
maintenance of this structure in muscle.  In order to test whether restoration of 
dystroglycan ligand binding activity in the postsynaptic membrane was sufficient 
for the maintenance of neuromuscular junction architecture, these structures 
were examined in TG-LARGEmyd mice and compared to those in wild-type and 
LARGEmyd muscle.   While all NMJs observed in LARGEmyd muscle were 
fragmented, NMJs in both wild-type and LARGEmyd muscle demonstrated the 
characteristic pretzel-like appearance which indicated that only postsynaptic 
dystroglycan glycosylation was essential for maintenance of this synapse.   
In order to determine the physiological consequence of impaired NMJ 
structure in LARGEmyd muscle, a paired-analysis approach was utilized in order 
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to assay for deficits in neurotransmission.   Maximal force production was 
measured twice in each gastrocnemius muscle, once during stimulation of the 
sciatic nerve and again following direct stimulation of the muscle.  In wild-type 
animals, maximum force production was achieved during nerve stimulation, and 
direct muscle stimulation yielded only a slight decrement in force production.  
However, nerve stimulation in LARGEmyd muscle resulted in less force production 
than was capable of being generated during direct muscle stimulation.  In direct 
contrast, maximum forces generated in TG-LARGEmyd animals occurred during 
nerve stimulation which indicated a complete structural and functional rescue of 
the NMJ in these animals.  These results indicate that the impaired structure of 
the NMJ observed in LARGEmyd mice yields a functional deficit that can be 
rescued via specific glycosylation of dystroglycan at the postsynaptic membrane. 
In addition to a complete rescue of the structure and function of the NMJ 
in TG-LARGEmyd animals, the peripheral neuropathy that has also been reported 
in LARGE-deficient animals was also rescued.  Using both assays of nerve 
function and motor performance, in addition to direct conduction velocity 
measurements in the sciatic and sural nerves, no deficits were observed in TG-
LARGEmyd animals.  This was an unexpected finding considering several studies 
that have demonstrated a critical function of dystroglycan as a laminin receptor in 
normal Schwann cell function.  During peripheral nerve development and 
following nerve crush, expression of both laminin and dystroglycan is increased 
in Schwann cells which suggests the importance of their interaction during 
myelinogenesis (238).  Interactions between dystroglycan and laminin are also 
hypothesized to be important for radial sorting of axons which would explain the 
presence of clusters of unmyelinated axons in LARGEenr nerves (145).  Mutations 
in either laminin-211 or laminin-411 impair radial sorting of axons (218, 219) and 
radial sorting defects are more severe in the absence of both laminin-211 and 
laminin-411 (220), which suggests that different aspects of the radial sorting 
process may be mediated by multiple laminin isoforms and their different 
receptors which include both dystroglycan and integrins.   Additionally, loss of 
function of laminin receptors may perturb laminin-mediated signaling required for 
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Schwann cell proliferation (220).   The dy2J/dy2J model of laminin deficiency 
demonstrates both radial sorting and myelination defects in conjunction with 
impaired nerve conduction velocity, clustering of sodium channels, and nodal 
structure (134) which is quite similar to defects observed in the Schwann cell 
specific deletion of dystroglycan (133).  While these studies highlight an 
importance of dystroglycan glycosylation for normal radial sorting and 
myelination of neurons during development, it is important to note that not all 
nerve defects reported in DG-null animals are consistent with the exclusive 
glycosylation-dependent function of dystroglycan in the PNS.  Although Schwann 
cell-specific dystroglycan-null animals demonstrate defects in node elongation 
and sodium channel clustering (133, 145), this has not been reported in either 
LARGEmyd or LARGEenr animals which suggests that glycosylation of 
dystroglycan is not essential for the formation of nodal domains. 
Although impaired peripheral nerve function was not detected in 
transgenic LARGEmyd animals, this does not rule out the importance of 
glycosylation-dependent functions of dystroglycan since defects in myelination 
have been observed in LARGEenr mice (145) and in other models of 
glycosyltransferase deficiency (146).  Rather, defects in myelination are likely 
variable along the length of the axon and would be expected to be progressive in 
nature.  This could be further tested in LARGEmyd animals by analyzing additional 
or more proximal regions of peripheral nerve.  Because LARGEmyd animals do 
not often survive past 40 weeks of age, this time point was used to test for both 
functional and histological evidence of neuropathy in all animals analyzed.  
However, because TG-LARGEmyd animals are presently surviving much longer 
than LARGEmyd animals, these mice can be analyzed at later time points and 
compared to wild-type littermates.  Anecdotally, the hindlimb paralysis that is 
commonly observed in older LARGEmyd animals has not yet been observed in 
TG-LARGEmyd, despite their having survived nearly twice as long as LARGEmyd 
animals, which suggests that the onset of neuropathy is either delayed or 
completely absent.  
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A possible explanation that might account for the observed rescue of 
nerve function may be related to the improvement in either muscle function or 
restored structure of the neuromuscular synapse.  While a deficit in nerve 
conduction velocity was observed in LARGEmyd sciatic nerve, sural nerve function 
was not different from wild-type animals.  Therefore, if the impaired muscle 
function of LARGEmyd animals negatively influenced motor neuron function, this 
might explain impaired conduction velocity specific to the motor sciatic nerve.  
Maintenance of neuronal connections can be dependent upon target-derived 
retrograde signals such as neurotrophins (223) that may act on peripheral nerves 
to maintain normal structure and function.   Skeletal muscle is a source of several 
neurotrophins including brain-derived neurotrophic factor (BDNF), glial-derived 
neurotrophic factor (GDNF), and neurotrophin-3/4 (224-228) which may 
contribute to motor neuron survival and/or differentiation (229).  There is also 
evidence to support the hypothesis that impaired neurotrophin signaling may be 
relevant in the muscular dystrophies.  Brains from mdx mice demonstrate 
increased staining of both nerve growth factor (NGF) and its receptor (230).  
Additionally, NGF is more highly expressed in regenerating fibers of patients with 
Duchenne/Becker muscular dystrophy as compared to healthy controls (231).  
More recently, the NGF precursor, pro-NGF, was also shown to promote death of 
motor neurons, though the source was thought to be from astrocytes (239).  In 
addition to promoting neuron survival, neurotrophins can also regulate 
myelination of the peripheral nervous system (240-242).  Neuregulin-1 is a 
growth factor produced in both the central and peripheral nervous system that 
binds receptors on myelinating Schwann cells to promote growth and 
differentiation during myelination (243).   
While it is intriguing to speculate that disruptions in neurotrophin related 
signaling may contribute to muscle weakness in muscular dystrophy (244), this 
hypothesis has yet to be formally addressed.  One possibility to explain the 
rescue of nerve function in transgenic LARGEmyd muscle might be that poor 
muscle function in LARGEmyd muscle results in impaired secretion of 
neurotrophins important for maintenance of the neuromuscular synapse.  BDNF 
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is secreted from skeletal muscle in an activity dependent manner (245) and 
contributes to synaptic potentiation at the neuromuscular junction (246).  
Additionally, muscle-specific expression or systemic injections of GDNF can 
cause multiple innervation of muscle fibers or slow the process of NMJ 
elimination (247).  To determine whether BDNF or GDNF expression is altered in 
LARGEmyd muscle and contributes to impaired neurotransmission deficits, whole 
muscle lysates or muscle sections from LARGEmyd, TG-LARGEmyd, and wild-type 
littermates could be used to screen for changes in BDNF of GDNF expression 
using RT-PCR or western blotting similar to what has been shown in dy/dy and 
mdx mice (230, 248).  In addition to potential changes in BDNF expression in the 
skeletal muscle of LARGEmyd mice, it would also be important to determine 
whether the expression of its known receptors, both TrkB and p75NTR, or 
activation of known downstream signaling molecules was altered in LARGEmyd 
neurons.  A reduction in BDNF or a downregulation of its receptors only in 
LARGEmyd muscle would suggest that an absence of BDNF-mediated signaling 
at the neuromuscular junction may contribute to impaired neurotransmission 
defects in LARGEmyd mice.  To more directly determine whether retrograde 
signaling mediated by neurotrophins is defective in LARGEmyd mice contributing 
to impaired function of the neuromuscular junction, specific neurotrophins could 
be directly applied in vivo and the consequences on gene transcription could be 
measured.  For example, Pazyra-Murphy et al. showed that in sensory neurons, 
the binding of neurotrophins to receptors on distal axons activated a large set of 
cell survival genes  termed “retrograde response genes” including MEF2D and 
bcl-w in the dorsal root ganglia (249).  Similarly, the transcription of these or 
other retrograde response genes could also be analyzed following muscle 
injection of specific neurotrophins in LARGEmyd  mice by using either RT-PCR or 
in situ hybridization in the dorsal horn of the spinal cord where motor neuron cell 
bodies are located.   
To more generally confirm that impaired neurotrophin signaling is a 
consequence of muscle degeneration and not a direct result of impaired 
glycosylation, it would be important to show that any neurotrophins identified as 
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being altered in LARGEmyd mice were similarly altered in other models of acute or 
chronic muscle damage.  Despite the known roles of NGF, BDNF and GDNF as 
neurotrophic factors, the mechanisms underlying retrograde signaling from the 
muscle to motor neurons have not been fully elucidated.  Therefore, gene 
expression profiling using microarrays from muscles of LARGEmyd and transgenic 
LARGEmyd  mice or additional mouse models of muscle disease may be a useful 
screen to identify secreted factors with known neurotrophic activity in other 
systems that may be important candidates for future study.   
Conclusions 
The results described in this thesis demonstrate that dystroglycan 
glycosylation is required for normal muscle function not only at the lateral 
membrane of muscle fibers but also at the postsynaptic membrane of the 
neuromuscular junction.   While the important mechanical function of DGC has 
been demonstrated in numerous studies, these results indicate that susceptibility 
to contraction-induced damage is not a characteristic of all DGC-related muscle 
dystrophies.  Additionally, this work is the first to demonstrate that dystroglycan 
has an essential glycosylation-mediated function at the neuromuscular junction 
that, when impaired, contributes to skeletal muscle weakness.     
 Although mutations that affect dystroglycan function are rare, these results 
have significant implications regarding the molecular mechanisms underlying 
disease progression in other forms of muscular dystrophy.  A primary defect in 
sarcolemmal integrity is an attractive hypothesis to account for the observed 
dystrophy in DGC-related muscular dystrophy.  Mutations that affect the DGC 
render myofibers    permeable to calcium, creatine kinase and impermeant dyes 
and this is correlated with increased susceptibility to mechanical injury.  
However, the resistance of LARGEmyd soleus muscle to mechanical injury, 
despite the observation of several pathological features of muscular dystrophy, 
indicates that mechanical injury is not the initiating event in this muscle that 
eventually causes death of myofibers.  This observation supports several 
alternative hypotheses that purport a direct function of the DGC in either calcium 
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homeostasis independent of membrane tears, or in disrupted survival and growth 
signaling pathways.  Many strategies aimed at treating these disorders have 
been hindered by the mechanical nature of the mutated gene and the obstacle of 
safely restoring expression of a corrected version of the diseased gene 
throughout skeletal muscle.  Therefore, the identification of critical non-
mechanical functions of the DGC may highlight additional targets aimed at 
treating and eventually curing disease.  In addition to the direct prevention of 
muscular dystrophy, targeting muscle fiber rescue may also have a significant 
indirect impact on the function of nerves, and therefore may help prevent the 
overall progressive decrease in neuromuscular function with age. 
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Figure 5-1) Fiber-type specific functions of laminin receptors in skeletal 
muscle. Dystroglycan and α7β1 integrin are differentially expressed in extensor 
digitorum longus (EDL) and soleus muscle and have been implicated in several 
shared signaling pathways related to cell survival and growth.   
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Figure 5-2) Phenotypic outcome as a result of impaired dystroglycan 
function in neuronal tissues.  The structure of the dystrophin-glycoprotein 
complex (DGC) in LARGEmyd, wild-type, and TG-LARGEmyd in skeletal muscle is 
depicted.  The mechanical link formed by the DGC between the basal lamina and 
the cytoskeleton is disrupted in LARGEmyd skeletal muscle and restored in TG-
LARGEmyd mice. Despite the loss of function of dystroglycan as a laminin 
receptor in brain and peripheral nerve of TG-LARGEmyd animals, several 
parameters of neurological function are restored.
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